Document:

Amendment No. 13 to the Shareholders' Agreement

 Exhibit 10.45 
 AMENDMENT NO. 13 
 TO THE SHAREHOLDERS’ AGREEMENT OF KIRIN-AMGEN, INC. 
 This AMENDMENT NO. 13 TO THE SHAREHOLDERS’ AGREEMENT OF KIRIN-AMGEN, INC., dated as of June 28, 2007 (this “Amendment
Agreement”), which shall become effective at 12:01 A.M., Japan Standard Time, on July 1, 2007, is made and entered into by and among Kirin Brewery Company, Limited, a Japanese corporation to be renamed Kirin Holdings Company, Limited
on July 1, 2007 (“Kirin Holdings”), Kirin Pharma Company, Limited, a Japanese corporation (including any successors by way of merger, consolidation, Share Exchange or similar transaction, “Kirin Pharma”),
Amgen Inc., a Delaware corporation (“Amgen”), and Kirin-Amgen, Inc., a Delaware corporation (“Kirin-Amgen”). All capitalized terms used in this Amendment Agreement and not otherwise defined herein shall have
the meanings assigned to such terms in the Shareholders’ Agreement (defined below), as amended hereby. 
 RECITALS 
 A. Kirin Holdings, Amgen and Kirin-Amgen are parties to that certain Shareholders’ Agreement of Kirin-Amgen, Inc., dated May 11, 1984 (as
amended, the “Shareholders’ Agreement”), and Kirin Holdings and either or both of Amgen and Kirin-Amgen, as the case may be, are parties to certain other agreements listed in Appendix A to this Amendment Agreement (such other
agreements collectively, the “Kirin/Amgen Agreements”); 
 B. Kirin Pharma is a direct, wholly owned subsidiary of Kirin
Holdings; 
 C. The stockholders of Kirin Holdings have approved the effectuation by Kirin Holdings of a reorganization pursuant to which,
among other things, it will assign, convey and transfer to Kirin Pharma all or substantially all of the assets and liabilities relating to Kirin Holdings’ pharmaceuticals business, including all of the shares of capital stock of Kirin-Amgen
held by Kirin Holdings (the “Shares”) and the rights and obligations of Kirin Holdings under the Shareholders’ Agreement as amended hereby and each Kirin/Amgen Agreement, in each case by means of a “Kaisha-Bunkatsu”
effected in accordance with the Corporate Split Agreement listed on Appendix D attached hereto and pursuant to Section 757 of the Japanese Corporation Code (the “Reorganization”); 
 D. Following the Reorganization, Kirin Pharma will continue to be a direct, wholly owned subsidiary of Kirin Holdings; 
 E. The Shareholders’ Agreement and the Kirin/Amgen Agreements contain certain restrictions on Kirin Holdings’ ability to assign to third
parties its rights and obligations under the Kirin/Amgen Agreements; 
 F. Kirin Holdings has requested that Amgen consent to the assignment
by Kirin Holdings to Kirin Pharma of all of the rights and obligations of Kirin Holdings under each Kirin/Amgen Agreement; 

 NOW, THEREFORE, in order to facilitate the Reorganization and at the same time protect their respective
investments in Kirin-Amgen, the parties have agreed as follows: 
  

	1.	CONSENT AND WAIVER; AMENDMENT OF CERTIFICATE OF INCORPORATION; CERTIFICATES OF CORPORATE REGISTRIES; EXCLUSION FROM THE SCOPE OF THE REORGANIZATION 

1.01 Amgen Consent and Waiver 
 Subject to the terms and conditions of this Amendment Agreement, Amgen and Kirin-Amgen each hereby consent to the assignment by Kirin Holdings to Kirin Pharma, pursuant to the Reorganization and in the manner
described in the Reorganization Package, of all of the rights and obligations of Kirin Holdings under each Kirin/Amgen Agreement. 
 1.02
Amendment of Certificate of Incorporation 
 The parties to this Amendment Agreement hereby agree that, in order to
give full effect to Paragraph 17.03 of the Shareholders’ Agreement, as described in Section 2.09 below, the certificate of incorporation of Kirin-Amgen shall be amended and restated as of the date of this Amendment Agreement to conform to
Appendix B attached to this Amendment Agreement. Each Party to this Amendment Agreement shall take all actions and execute and deliver all documents and instruments (including written consents of Kirin Holdings and Amgen in their respective
capacities as stockholders of Kirin-Amgen), and shall cause the members of the board of directors of Kirin-Amgen to adopt all resolutions, take alnl actions and execute and deliver all documents and instruments, reasonably necessary to give full
effect to the provisions of this Section 1.02. 
 1.03 Exclusion from the Scope of the Reorganization 
 In accordance with the last sentence of Article 4(2) of the Corporate Split Agreement listed on Appendix D attached hereto, Kirin Holdings
and Kirin Pharma have discussed the exclusion of the Shares and the rights and obligations of Kirin Holdings under the Shareholders’ Agreement as amended hereby from the scope of the Reorganization and hereby agree that, notwithstanding
anything to the contrary contained in the Corporate Split Agreement, the Shares and the rights and obligations of Kirin Holdings under the Shareholders’ Agreement as amended hereby shall be excluded from the scope of the rights and obligations
being transferred from Kirin Holdings to Kirin Pharma as part of the corporate split contemplated in the Corporate Split Agreement. Notwithstanding anything to the contrary contained herein, the provision in this paragraph shall be governed by and
construed in accordance with the internal laws, and not the law of conflicts, of Japan applicable to agreements made and to be performed in Japan. 
 Kirin Holdings and Kirin Pharma, jointly and severally, represent and warrant to Amgen as of the date hereof that (a) the agreement of Kirin Holdings and Kirin Pharma in the immediately preceding paragraph
constitutes a valid and legally binding agreement of each of Kirin Holdings and Kirin Pharma enforceable against it in accordance with its terms, (b) the agreement of Kirin Holdings and Kirin Pharma in the immediately preceding paragraph
overrides anything to the contrary contained herein or in the Reorganization Package (including 

  

 2 

 
the Corporate Split Agreement) and (c) by virtue of the agreement of Kirin Holdings and Kirin Pharma in the immediately preceding paragraph, the Shares
and the rights and obligations of Kirin Holdings under the Shareholders’ Agreement as amended hereby will be retained by Kirin Holdings, and will not be transferred to Kirin Pharma, in the Reorganization, notwithstanding anything to the
contrary contained herein or in the Reorganization Package (including the Corporate Split Agreement). 
 1.04 Certificates of Corporate
Registries 
 Each of Kirin Holdings and Kirin Pharma shall deliver to counsel to Amgen at its office in Tokyo true and
complete certificates of their respective corporate registries, issued by a competent registrar office of the Ministry of Justice in Japan and describing the effectuation of the “Kaisha Bunkatsu” in accordance with the Corporate Split
Agreement listed on Appendix D hereto and pursuant to Section 757 of the Japanese Corporation Code, in each case promptly after the same becomes available (and, in any event, within two business days thereof). 
  

	2.	AMENDMENTS TO THE SHAREHOLDERS’ AGREEMENT 

 Effective as of the date of this Amendment Agreement, the Shareholders’ Agreement is hereby amended as follows: 
 2.01 Preamble 
 The Preamble of the Shareholders’ Agreement is amended by
(i) replacing the comma after the word “corporation” in the sixth line with the phrase “to be renamed Kirin Holdings Company and”, (ii) replacing the phrase “1900 Oak Terrace Lane” with the phrase “One
Amgen Center Drive”, and (iii) replacing the phrase “(“Kirin”),” with the phrase “(“Kirin” or “Kirin Holdings”), Kirin Pharma Company, Limited, a Japanese corporation having its principal
office at 26-1, Jingumae 6-chome, Shibuya-ku, Tokyo, Japan 150-8011 (including any successors by way of merger, consolidation, Share Exchange or similar transaction, “Kirin Pharma”),”. 
 2.02 Certain Definitions 
 Paragraph 1 of the Shareholders’ Agreement is amended by inserting (i) in Paragraph 1.10, after the word “Kirin,” in the first and third lines, the phrase “Kirin Pharma,”, (ii) in Paragraph 1.09, in the
place of the word “Kirin”, the phrase “Kirin Pharma” and (iii) after Paragraph 1.10, new Paragraphs 1.11 through 1.33 as follows: 
 1.11 Administrative Matters 
 The term Administrative Matters shall mean any matter
relating to the handling and resolution of intellectual property matters, legal matters and payment of expenses. 
 1.12
Affiliate 
 The term Affiliate shall mean, with respect to any Person, any Person directly or indirectly Controlling,
Controlled by, or under common Control with, such other Person as of the 

  

 3 

 
date on which, or at any time during the period for which, the determination of affiliation is being made. 
 1.13 Asian Country 
 The term Asian Country shall mean any of the jurisdictions specified in Appendix C attached to this Amendment Agreement, and the term Asian Countries shall mean all such jurisdictions collectively. 
 1.14 Asian Pharma Entity 
 The term Asian Pharma Entity shall mean any corporation that (i) is incorporated or otherwise organized under the laws of, and has its principal executive offices in, any Asian Country; (ii) derives at least
80% of its consolidated revenues from the development, manufacture, processing, distribution or sale of pharmaceutical or biotechnology products in Asian Countries; and (iii) is not Controlled, directly or indirectly, by a Non-Asian Pharma
Entity. 
 1.15 Average Two-Year Trailing Revenues 
 The term Average Two-Year Trailing Revenues with respect to any particular fiscal year shall mean the average of the total revenues and
other income of Corporation, as set forth in the audited annual financial statements of Corporation, for the two immediately preceding fiscal years. 
 1.16 Beneficial Owner 
 The term Beneficial Owner shall mean, with respect to any
Equity Securities, any Person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares (i) voting power, which includes the power to vote, or to direct the voting of, such Equity
Security; and/or (ii) investment power, which includes the power to dispose, or to direct the disposition of, such Equity Securities. The terms Beneficially Owned and Beneficial Ownership shall have corresponding meanings. In any dispute
between Amgen and Kirin concerning whether or not a Person who is not a record holder of Equity Securities is nonetheless a Beneficial Owner of such Equity Securities, Amgen shall have the burden of proving that such Person is a Beneficial Owner.

 1.17 Consumer Price Index 
 The term Consumer Price Index shall mean the Consumer Price Index for All Urban Consumers published by the Bureau of Labor Statistics of
the U.S. Department of Commerce, Los Angeles All Items (1982-1984=100), or any successor index thereto, appropriately adjusted. If the Consumer Price Index is converted to a different standard reference base or otherwise revised, then, whenever the
determination of a Consumer Price Index figure is called for herein, the Consumer Price Index shall be converted in accordance with the conversion factors published by the U.S. Department of Commerce, Bureau of Labor Statistics, or, if such Bureau
does not publish such conversion factors, the conversion factors published by any other nationally recognized publisher of similar statistical information determined by Amgen. 
  

 4 

 1.18 Control 
 The term Control, as used with respect to any Person, shall mean the possession, directly or indirectly, of the power to direct or cause
the direction of the management policies of such Person, whether through the ownership of voting securities or by contract or otherwise. The phrases Controlled by and under common Control with shall have corresponding meanings. 
 1.19 Control Event 
 The term Control Event shall mean any of the following: (i) the first date on which the shares of common stock of Kirin Pharma held of record by Kirin Holdings of which Kirin Holdings is a Beneficial Owner cease
to constitute at least 2/3 (two thirds) of the total number of shares of common stock of Kirin Pharma on a fully diluted basis or cease to represent at least 2/3 (two thirds) of the votes entitled to be cast on any matter by holders of Equity
Securities of Kirin Pharma; provided that, in the event but only in the event that Kirin Pharma consummates a Qualified Public Merger or Qualified Public Offering, as of and from the time of such consummation this clause (i) shall automatically
be amended to replace each of the two instances of the phrase “2/3 (two thirds)” above (but not the instance of that phrase below) with the phrase “a majority”; provided, further, that, if Kirin Holdings acquires a majority of
the outstanding Equity Securities of a corporation (a majority of the Equity Securities of which corporation are listed for trading on a recognized national or international securities exchange) (“Target”) and concurrently therewith
or thereafter contributes all of the outstanding common stock of Kirin Pharma to the Target with the result that all of the outstanding common stock of Kirin Pharma is owned by Target (such a transaction, a “Transitional
Transaction”), then the fact that Kirin Holdings owns of record less than 2/3 of the outstanding common stock of Kirin Pharma shall not constitute a Control Event if (x) the Target holds of record all of the outstanding shares of
common stock of Kirin Pharma, (y) Kirin Holdings holds of record a majority of the outstanding Equity Securities of Target, and (z) within 365 days following Kirin Holdings’ contribution to Target of shares of common stock of Kirin
Pharma, Kirin Pharma is merged into Target in a transaction constituting a Qualified Public Merger, (ii) the first date on which Kirin Holdings ceases to have the ability to elect at least a majority of the members of the board of directors of
Kirin Pharma; provided that, in the event that Kirin Holdings, Kirin Pharma and a Target enter into a Transitional Transaction, the fact that Kirin Holdings ceases to have the direct ability to elect at least a majority of the members of the board
of directors of Kirin Pharma shall not constitute a Control Event if (x) the Target has the ability to elect all of the directors of Kirin Pharma, (y) Kirin Holdings has the ability to elect a majority of the directors of Target, and
(z) within 365 days following Kirin Holdings’ contribution to Target of shares of common stock of Kirin Pharma, Kirin Pharma is merged into Target in a transaction constituting a Qualified Public Merger, (iii) the consummation of any
Restricted Transaction or, if earlier, the public announcement, execution or delivery of any agreement, plan or proposal contemplating any Restricted Transaction, in any such case without the prior written consent of Amgen, or (iv) to the
extent that Kirin Holdings or Kirin Pharma consummates a transaction or series of transactions that, but for the fact that it was entered into with a Qualified Third Party or Non-Pharma Entity, would have constituted a Restricted Transaction, the
first date on which such Qualified Third Party ceases to be an Asian Pharma Entity or such Non-Pharma Entity ceases to be a Non-Pharma Entity. 
  

 5 

 1.20 CPI Adjustment 
 The term CPI Adjustment shall mean an adjustment of the FTE Rate, which shall be made by first multiplying such FTE Rate by the Consumer
Price Index in effect as of the effective date of such adjustment and then dividing the resulting product by the Consumer Price Index in effect as of the later of the date of this Amendment Agreement and the date as of which the FTE Rate was last
adjusted. 
 1.21 Equity Securities 
 The term Equity Securities shall mean, with respect to any Person other than a natural person, any shares of capital stock or other
ownership interests of such Person and the securities convertible into or exchangeable or exercisable for or into any such shares or ownership interests. 
 1.22 FTE Rate 
 The term FTE Rate shall mean the rate used by the Parties to reimburse
Kirin Pharma and Amgen for personnel-related expenses incurred by them in connection with their respective research and development activities. 
 1.23 Group 
 The term Group means any group of Persons acting in concert with respect
to the acquisition, ownership or disposition of Equity Securities. 
 1.24 Kirin-Amgen Matter 
 The term Kirin-Amgen Matter shall mean, collectively, any Administrative Matter, any matter relating to Corporation under consideration by
the primary business representatives of Amgen, on the one hand, and Kirin Holdings or Kirin Pharma, on the other hand, any matter or question required to be decided or acted upon by the Board of Directors or stockholders of Corporation and any
matter requiring the consent of any of the Parties pursuant to this Agreement or any other agreement between or among Amgen, on the one hand, and Kirin Holdings or Kirin Pharma, on the other hand, related to Corporation or to the Products (as
defined in Section 17.04.1). 
 1.25 Non-Asian Pharma Entity 
 The term Non-Asian Pharma Entity shall mean (i) any Person that derives 50% or more of its consolidated revenues from the
development, manufacture, processing, distribution or sale of pharmaceutical or biotechnology products outside of Asian Countries, and (ii) any Person Controlled, directly or indirectly, by any Person described by clause (i) of this
sentence. 
 1.26 Non-Pharma Entity 
 The term Non-Pharma Entity shall mean any Person that (i) derives less than 10% of its consolidated revenues from the development,
manufacture, processing, distribution or sale 

  

 6 

 
of pharmaceutical or biotechnology products, and (ii) if Controlled, is not Controlled, directly or indirectly, by any Person other than a Person
described by clause (i) of this sentence. 
 1.27 Person 
 The term Person shall mean an individual, a corporation, a partnership, an association, a limited liability company, joint venture,
estate, trust or other entity of any kind or nature. 
 1.28 Purchase Event 
 The term Purchase Event shall mean the first date on which shares of common stock of Kirin Pharma held of record by Kirin Holdings of
which Kirin Holdings is a Beneficial Owner cease to constitute at least [*] of the total number of shares of common stock of Kirin Pharma on a fully diluted basis or cease to represent at least [*] of the votes entitled to be cast on any matter by
holders of Equity Securities of Kirin Pharma; provided that, if Kirin Holdings acquires [*] of the outstanding Equity Securities of Target and concurrently therewith or thereafter consummates a Transitional Transaction, then the fact that Kirin
Holdings owns of record less than [*] of the outstanding common stock of Kirin Pharma shall not constitute a Control Event if (i) Target holds of record [*] of the outstanding shares of common stock of Kirin Pharma, (ii) Kirin Holdings
holds of record [*] of the outstanding Equity Securities of Target, and (iii) within [*] days following Kirin Holdings’ contribution to Target of shares of common stock of Kirin Pharma, Kirin Pharma is merged into Target in a transaction
constituting a Qualified Public Merger. 
 1.29 Qualified Public Merger 
 The term Qualified Public Merger shall mean any merger, consolidation or Share Exchange of Kirin Pharma with or into any other corporation
(a majority of the Equity Securities of which corporation are listed for trading on a recognized national or international securities exchange) after the consummation of which merger, consolidation or Share Exchange at least 30% but less than 50% of
the total number of shares of common stock of Kirin Pharma, calculated on a fully diluted basis, are listed for trading on a recognized national or international securities exchange; provided, however that after the consummation of a Qualified
Public Merger (other than Share Exchange) in which Kirin Pharma is not the surviving corporation, all references to shares of common stock of Kirin Pharma herein shall be deemed to be references to shares of common stock of such surviving
corporation. 
 1.30 Qualified Public Offering 
 The term Qualified Public Offering shall mean a public offering, registered under the Securities and Exchange Law of Japan and conducted
on a “firm commitment” basis for an aggregate offering price of not less than ¥5 billion, of shares of common stock of Kirin Pharma that upon completion of such offering will be listed on the Tokyo Stock Exchange and will represent at
least 30% but less than 50% of the total number of shares of common stock of Kirin Pharma on a fully diluted basis.
  

 7 

 1.31 Qualified Third Party 
 The term Qualified Third Party shall mean any Asian Pharma Entity that is not making or asserting and, within the past five years, has not
made or asserted, against Amgen or any of its Affiliates or any of their significant subsidiaries, in any written communication, action, suit, proceeding or arbitration, any claim which, if resolved other than in Amgen’s favor, could materially
and adversely affect the business, assets, business relationships, prospects, financial condition or results of operations of Amgen or any such Affiliate or significant subsidiary. 
 1.32 Restricted Transaction 
 The term Restricted Transaction shall mean any transaction or series of transactions (including but not limited to any issuance, sale, transfer, assignment, pledge, hypothecation or other disposition or encumbrance of
securities or other assets or property, and any merger, consolidation, Share Exchange, reorganization, recapitalization or reverse stock split) as a result of which any Person or Group (other than Kirin Holdings or an employee of Kirin Pharma)
(i) is or will become the Beneficial Owner of (A) any Equity Securities of Kirin Pharma and such Beneficial Ownership could affect the management or business of Corporation, or (B) any Equity Securities of Corporation, or
(ii) possesses or will possess the right to appoint one or more members of the board of directors of (A) Kirin Pharma, where the existence or exercise of such rights could affect the management or business of Corporation, or
(B) Corporation, other than any (v) issuance, sale or transfer of Equity Securities of Kirin Holdings to any Qualified Third Party or Non-Pharma Entity, (w) merger, consolidation, Share Exchange or similar business combination
transaction between Kirin Holdings, on the one hand, and any Qualified Third Party or Non-Pharma Entity, on the other, (x) Qualified Public Merger, or (y) Qualified Public Offering, or (z) Transitional Transaction in which
(I) the Target holds of record all of the outstanding shares of common stock of Kirin Pharma, (II) Kirin Holdings holds of record a majority of the outstanding Equity Securities of Target, (III) the Target has the ability to elect all of the
directors of Kirin Pharma, (IV) Kirin Holdings has the ability to elect a majority of the directors of Target, and (V) within 365 days following Kirin Holdings’ contribution to Target of shares of common stock of Kirin Pharma, Kirin Pharma
is merged into Target in a transaction constituting a Qualified Public Merger. 
 1.33 Share Exchange 
 The term Share Exchange shall mean a kabushiki-kokan or kabushiki-iten, as those terms are currently construed under the
Japanese Corporation Code. 
 2.03 Qualification of Board Members 
 Paragraph 12.01 of the Shareholders’ Agreement is amended by inserting after the second sentence thereof, the following sentence:
“Each member of the Board of Directors of Corporation (and each candidate therefor nominated by Kirin or Amgen) shall be an employee of Kirin or one of its subsidiaries or Amgen or one of its subsidiaries, as the case may be.” 

2.04 Shareholder Consultation 
 Paragraph 12 of the Shareholders’ Agreement is amended by inserting, after Paragraph 12.03, Paragraphs 12.03A and 12.03B as follows: 
  

 8 

 “12.03A Administrative Decision-Making 
 The Parties shall cause all Administrative Matters to be handled in a manner consistent with their respective past practices. 

12.03B Decision Deadlocks 
 12.03B.1 If, with respect to any Kirin-Amgen Matter, the representatives of the applicable Parties are unable to reach agreement within [*] calendar days following the date on which such Kirin-Amgen Matter is first
notified by one Party to the other Party, then either such Party shall be entitled to implement the consultation process contemplated by this Paragraph by giving written notice to the other Party (each, an “Escalation Notice”).

 12.03B.2 Within [*] calendar days following receipt of an Escalation Notice, the applicable Parties shall cause such
Kirin-Amgen Matter to be referred to the President and the Chairman of Corporation (or such designees who have decision-making authority with respect to such Kirin-Amgen Matter), and the applicable Parties shall cooperate to cause such President and
Chairman (or their designees) to resolve such disagreement in good faith within [*] calendar days following the date of the related Escalation Notice. 
 12.03B.3 If the President and the Chairman of Corporation are unable to reach agreement on such Kirin-Amgen Matter during such period, the applicable Parties shall cause such Kirin-Amgen Matter to be referred to the
attendees of Kirin and Amgen at the first succeeding executive business meeting of Corporation and the applicable Parties shall cooperate to cause such attendees to resolve such disagreement in good faith at such executive business meeting.

 12.03B.4 If such attendees are unable to resolve such disagreement at such meeting, within [*] calendar days following such
meeting, the applicable Parties shall cause such Kirin-Amgen Matter to be referred to the respective Chief Executive Officers of Kirin and Amgen, and the applicable Parties shall cooperate to cause such Chief Executive Officers to resolve such
disagreement in good faith within [*] calendar days following the date of the preceding executive business meeting. 
 12.03B.5 If the authorized representatives of the applicable Parties reach agreement with respect to such Kirin-Amgen Matter pursuant to this Paragraph, Kirin and Amgen shall take such actions as are necessary to cause Corporation to
implement such decision. If the Chief Executive Officers of Kirin and Amgen are unable to reach agreement on such Kirin-Amgen Matter, neither Corporation nor its Board of Directors or Officers shall be required to take any action in connection
therewith.” 
 2.05 Management 
 (a) Paragraph 12.06 of the Shareholders’ Agreement is amended by replacing the phrase “Kirin and/or Amgen” in the seventh line thereof with the phrase “any of the Parties”. 
 (b) Paragraph 12.07 of the Shareholders’ Agreement is amended by replacing the phrase “Kirin and/or Amgen” in the fourth
line thereof with the phrase “any of the Parties”. 
  

 9 

 (c) Paragraph 12.10 of the Shareholders’ Agreement is amended by inserting, after
the word “Kirin”, the phrase “, Kirin Pharma”. 
 2.06 Business Matter 
 (a) Paragraph 13.01 of the Shareholders’ Agreement is amended by (i) replacing the phrase “Kirin and Amgen” in the
second line thereof with the phrase “the Parties”, and (ii) replacing the word “Kirin” in the first line of clause (i), and the second, fifth and eleventh lines of clause (iii) with the phrase “Kirin Pharma”.

 (b) Paragraphs 13.02 and 13.03 of the Shareholders’ Agreement are amended by replacing each instance of the word
“Kirin” with the phrase “Kirin Pharma”. 
 2.07 Restrictions on Shares 
 (a) Paragraph 14.01 of the Shareholders Agreement is amended by deleting the words “in any other way dispose of or” and “,
voluntarily and involuntarily, by bankruptcy, operation of law or otherwise” in the sixth through eighth lines thereof. 
 (b) Paragraph 14.02 of the Shareholders’ Agreement is deleted in its entirety. 
 (c) Paragraphs 14.03 and 14.04
of the Shareholders’ Agreement are amended and restated as follows: 
 “14.03 Purchase Price 
 For purposes of Paragraphs 14.01 above and 17.04 below, the “Purchase Price” to be paid for the shares (the
“Purchase Shares”) of the transferring shareholder (the “Transferor”) shall be as follows: 
 (i) The Purchase Price shall be [*], and shall be determined in United States dollars as of a date not later than [*] calendar days following the date of the notice in writing (each, an “Exercise Notice”) provided by the
Nontransferring Shareholder or Amgen, as the case may be (the “Transferee”), pursuant to Paragraph 14.03 or 17.04, as the case may be; provided that, if such determination is made by [*] in accordance with Paragraph 14.03(ii),
such determination shall be made as of the month preceding the date on which such [*] is made. 
 (ii) The Purchase Price
shall be determined, if possible, by the mutual agreement of the Transferor and Transferee in accordance with the definition set forth in Paragraph 14.03(i). If Transferor and Transferee are unable to reach agreement within [*] calendar days
following the date of the Exercise Notice, the Purchase Price shall be determined by [*]. If Transferor and Transferee are unable to [*], each shall choose [*] and the [*] shall, in good faith, select [*]. The [*] so selected shall determine the
Purchase Price, which determination shall be final and binding on Transferor and Transferee. If either Transferor or Transferee fail to select [*] within [*] calendar days after receipt of notice from the other Party specifying such failure, such
other Party may select [*] in its sole discretion to determine the Purchase Price, which determination shall be final and binding on Transferor and Transferee. Transferor and Transferee shall instruct the [*] so retained to deliver a written opinion
as to the Purchase Price to each of them within [*] 

  

 10 

 
calendar days following the selection of the [*]. The cost of determining the Purchase Price, including the fees and expenses of the [*], shall, unless
otherwise agreed by Transferor and Transferee in writing, be borne [*]. 
 (iii) Corporation agrees to furnish the [*]
retained pursuant to Paragraph 14.03(ii) with such financial, business or other information as is reasonably necessary to allow it to evaluate the business, financial condition and results of operations of Corporation, subject to execution of a
reasonable confidentiality agreement between Corporation and such [*]. 
 14.04 Purchase Closing 
 (i) The consummation of the purchase and sale of the Purchase Shares (the
“Purchase Closing”) shall occur on the 15th calendar day (or, if such 15th calendar day is not a business day, the next succeeding business day) following the last to occur of (i) the final determination of the Purchase Price, and (ii) the receipt of any governmental and
regulatory approvals required for the consummation of the Purchase Closing, at 10:00 a.m., California time, at the principal executive office of Transferee. At the Purchase Closing, the Transferor shall deliver to Corporation a share certificate or
share certificates evidencing the Purchase Shares, endorsed for transfer to the Transferee, and a notice of transfer sufficient to effect the transfer of the Purchase Shares to the Transferee, and the Transferee shall deliver the Purchase Price to
the Transferor in cash, by wire transfer or by certified or official bank check, in any case denominated in United States dollars, and the transfer of the ownership of the Purchase Shares shall be duly recorded in the share register of Corporation.

 (ii) The consummation of such transaction shall constitute (i) a warranty by the Transferor to the
Transferee that, as of the Purchase Closing, all such Purchase Shares shall be duly authorized, validly issued and fully paid and that the sale and delivery of the Purchase Shares at the Purchase Closing shall vest in the Transferee good legal title
and beneficial ownership of the Purchase Shares, free and clear of all liens, charges, encumbrances, usufructs, restrictions, options and other claims, and (ii) an agreement by the Transferee to indemnify the Transferor and hold it harmless
against any losses or damages arising out of the foregoing warranty.” 
 2.08 Endorsement of Certificates 
 Section 16 of the Shareholders’ Agreement is amended by replacing the word “Kirin” with the phrase “Kirin
Holdings, Kirin Pharma”. 
 2.09 Additional Provisions 
 Section 17 of the Shareholders’ Agreement is amended and restated as follows: 
 “17. ADDITIONAL PROVISIONS 
 17.01 Restricted Transactions 
 Neither Kirin nor Kirin Pharma shall, without the
prior written consent of Amgen, consummate, publicly announce, execute or deliver any agreement, plan or proposal 

  

 11 

 
contemplating any Restricted Transaction or take or permit any action or suffer to exist any event, condition or circumstance that is reasonably likely to
result in any Restricted Transaction. 
 17.02 Control Event 
 Kirin shall provide Amgen with confidential written notice (containing, with respect to an event referred to in clause (a), a reasonably
detailed description of the proposed agreement or transaction) of (a) its expected entry into any agreement or transaction providing for a Control Event, not later than [*] calendar days prior to entering into such agreement or transaction, and
(b) the occurrence of a Control Event within [*] calendar days following such occurrence. Upon the occurrence of a Control Event: 
 17.02.1 Corporation shall at Amgen’s option, which it may exercise by giving written notice thereof at any time on or prior to the [*] calendar day following its receipt of notice of the occurrence of such
Control Event, immediately issue and deliver to Amgen one share of preferred stock having the terms set forth in Article Fifth of Corporation’s Amended and Restated Certificate of Incorporation to be filed on or about June 29, 2007 (such
share, the “Control Share” and such Amended and Restated Certificate of Incorporation, the “Restated Charter”), and Amgen shall promptly pay to Corporation, against the delivery thereof, the par value thereof.
Amgen, Kirin Holdings and Kirin Pharma hereby irrevocably consent to such issuance of the Control Share in accordance with Paragraph 2.13.1. 
 17.02.2 Upon the issuance to Amgen of one share of preferred stock of Corporation pursuant to Paragraph 17.02.1, the number of members of the Board of Directors of Corporation shall automatically increase to seven
directors pursuant to Article Eighth of the Restated Charter, and Amgen, in its capacity as holder of all of the outstanding shares of preferred stock, shall promptly nominate, designate and elect the member of the board of directors of Corporation
entitled to be nominated, designated and elected by holders of such shares pursuant to paragraph (a) of Article Fifth of the Restated Charter. 
 17.02.3 Each Party shall take all actions, and execute and deliver all documents and instruments, reasonably necessary to give full effect to the provisions of this Paragraph 17.02 and the Restated Charter.

 17.03 Purchase Event 
 Kirin shall provide Amgen with confidential written notice (containing, with respect to an event referred to in clause (a), a reasonably detailed description of the proposed agreement or transaction) of (a) its
expected entry into any agreement or transaction providing for a Purchase Event, not later than [*] calendar days prior to entering into such agreement or transaction, and (b) the occurrence of a Purchase Event within [*] calendar days
following such occurrence. Such notice shall be deemed given when such notice is received. 
 Upon the occurrence of a
Purchase Event, (i) Amgen shall have the option, which it may exercise by giving written notice thereof to Kirin and Corporation at any time on or prior to the [*] calendar day following its receipt of notice of the occurrence of such Purchase
Event, to elect to purchase [*] of the Equity Securities of Corporation held by Kirin (the “Kirin Shares”) in accordance with Paragraphs 14.03 and 14.04, as amended, and (ii) the Corporation shall be 

  

 12 

 
entitled to, and Amgen may (by written notice given, in its sole discretion, on Corporation’s behalf), at any time following such occurrence, terminate
any or all of the agreements between Corporation, on the one hand, and Kirin and/or Kirin Pharma, on the other hand, including any or all of the Kirin/Amgen Agreements, and each such agreement is hereby amended to so provide. 
 17.04 R&D Funding & Reimbursement Obligations 
 17.04.1 Corporation shall, and Kirin and Amgen shall cooperate to cause Corporation to, (i) authorize Amgen to incur expenses on
Corporation’s behalf, in each calendar year specified in the table below, in respect of research and development activities conducted by Amgen in relation to indications presented to the Board of Directors of Corporation prior to July 1,
2007 of any of [*] (each as defined in the applicable amendment to this Agreement and the related agreements between or among one or more of the Parties and, collectively, the “Products”), up to at least the aggregate expense amount
set forth opposite such calendar year in the second column of the table below, and (ii) authorize Kirin Pharma to incur expenses on Corporation’s behalf, in each calendar year specified in the table below, in respect of research and
development activities conducted by Kirin Pharma in relation to such indications of the Products, up to at least the aggregate expense amount set forth opposite such calendar year in the third column of the table below. Corporation shall account for
such authorized expenses in accordance with U.S. generally accepted accounting principles and shall reimburse Amgen and Kirin Pharma therefor in accordance with past practice. Each such aggregate expense amount shall be allocated among Amgen’s
or Kirin Pharma’s research and development activities relating to such indications of the Products in a manner determined by Amgen or Kirin Pharma, as the case may be, in its sole discretion, and each such Party shall provide Corporation with
reasonable notice of such allocation. 
  

					
	 Year
	  	Amgen 
Aggregate
Expense Amount	 	Kirin Pharma
Aggregate
Expense Amount
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]

 Any expenses that Amgen or Kirin Pharma incurs on behalf of Corporation in respect
of research and development activities relating to such indications of the Products that are in excess of such aggregate expense amount shall require the approval of the Board of Directors of Corporation. Notwithstanding anything to the contrary
herein, [*]. 
 17.04.2 Corporation shall, and Kirin and Amgen shall cooperate to cause Corporation to, authorize each of
Kirin Pharma and Amgen to incur expenses on Corporation’s behalf, in each calendar year from [*] through 2019, in respect of research and development activities conducted by Kirin Pharma and/or Amgen in relation to the Products, up to at least
an aggregate expense amount equal to [*] of the [*] of Corporation applicable to such calendar year. Corporation shall account for such authorized expenses in accordance with U.S. generally accepted accounting principles and shall reimburse Kirin
Pharma and/or Amgen therefor in accordance with past practice. Each such aggregate expense amount shall be allocated among Kirin Pharma’s and Amgen’s respective research and development activities relating to the 

  

 13 

 
Products in a manner determined by the Board of Directors of Corporation in its sole discretion. In the event that the Board of Directors of Corporation is
unable to reach agreement on such allocation, the applicable aggregate expense amount shall be allocated among Kirin Pharma and Amgen’s respective research and development activities in proportion to the previous year’s allocation.

 17.04.3 If at any time the revenue of Corporation, together with any cash on hand, is insufficient to fund the payment
obligations of Corporation under this Paragraph 17.04, then Kirin and Amgen shall make capital contributions to Corporation, ratably according to the number of shares of common stock of Corporation held by each of them, in an aggregate amount equal
to the amount by which such payment obligation exceeds such income and cash on hand and otherwise in accordance with Paragraph 2.13. Each of Kirin and Amgen shall have the right to deduct from any amounts (including royalties) owed by such Party to
Corporation pursuant to any agreement between such Party and Corporation any unpaid amounts required to be paid by Corporation pursuant to this Paragraph 17.04. 
 17.05 FTE Rates 
 Corporation agrees, and Kirin and Amgen agree to cause Corporation to, adjust the FTE Rate by means of a CPI Adjustment effective as of January 1 of each calendar year; provided that, unless otherwise agreed by
Kirin and Amgen in writing, in no event shall any FTE Rate be reduced to an amount less than the prior year’s FTE Rate.” 
 2.10
Export Control Laws 
 Paragraph 19.02 of the Shareholders’ Agreement is amended by replacing the word
“Kirin” with the phrase “Kirin Pharma”. 
 2.11 Entire Agreement; Amendment 
 Paragraph 22.03 of the Shareholders’ Agreement is amended by replacing the phrase “Kirin, Amgen and the Corporation” in the
second sentence thereof with the phrase “each Party”. 
 2.12 Notices 
 Paragraph 22.01 of the Shareholders’ Agreement is amended and restated as follows: 
 “All notices, requests, demands and other communications required or permitted to be given under this Agreement shall be in writing
and shall be addressed to the following: 
  

 14 

			
	 “Kirin Holdings”
	  	Kirin Holdings Company, Limited
		  	10-1, Shinkawa 2-chome, Chuo-ku
		  	Tokyo, 104-8288, Japan
		
		  	Attention: General Manager, Corporate Planning Department
		  	Facsimile No.: +81-3-5540-3587
		  	Telephone No.: +81-3-5540-3424
		
	 “Kirin Pharma”
	  	Kirin Pharma Company, Limited
		  	26-1, Jingumae 6-chome, Shibuya-ku
		  	Tokyo, 150-8011, Japan
		
		  	Attention: General Manager, Planning Department
		  	Facsimile No.: +81-3-5485-6301
		  	Telephone No.: +81-3-5485-6765
		
	 “Amgen”
	  	Amgen Inc.
		  	One Amgen Center Drive
		  	Thousand Oaks, California 91320-1799, United States
		  	Attention: General Counsel
		  	Facsimile No.: +1-805-499-6751
		  	Telephone No.: +1-805-447-1000
		
	 “Corporation”
	  	Kirin-Amgen, Inc.
		  	c/o Amgen Inc.
		  	One Amgen Center Drive
		  	Thousand Oaks, California 91320-1799, United States
		
		  	Attention: President of Kirin-Amgen
		  	Facsimile No.: +1-805-499-6751
		  	Telephone No.: +1-805-447-1000

 Either Party may change its address to which notices shall be sent by giving notice to the other Party in the
manner herein provided. Any notice required or provided for by the terms of this Agreement shall be in writing and shall be (a) sent by means of “next day” air express delivery via a reputable international overnight courier service,
or (b) sent by facsimile transmission, in each case properly addressed in accordance with the paragraph above. The effective date of notice shall be the actual date of receipt by the Party receiving the same.” 
 2.13 Publicity and Disclosure 
 Paragraph 22.02 of the Shareholders’ Agreement is amended and restated as follows: 
 “22.02
Confidential Information; Disclosure and Publicity 
 22.02.1 Each Party agrees not to, and agrees to cause such
Party’s directors, 

  

 15 

 
officers, employees, etc. not to, disclose or permit the disclosure to any third party of any confidential, non-public or proprietary information relating to
the business of Corporation or any other Party (collectively, “Confidential Information”); provided that such disclosure may be made (i) with the prior written consent of Kirin and Amgen, (ii) to any Person who is a
director, officer, employee, attorney, agent, consultant or accountant of a Party who needs to know such information for the purposes of this Agreement and in connection with the conduct of the business of Corporation, and agrees to be bound by such
Party’s confidentiality obligations hereunder, (iii) subject to Paragraph 22.02.2, pursuant to a subpoena or order issued by a court, arbitrator or governmental body, agency or official, or (iv) subject to Paragraph 22.02.3, to the
extent required by applicable law or by the rules of any securities exchange. 
 22.02.2 In the event that a Party or any of
its Affiliates is required to disclose any Confidential Information in connection with any judicial or administrative proceedings (by oral questions, interrogatories, requests for information or documents, subpoena, civil investigation demand or
similar process), that Party in advance of such disclosure shall provide the other Parties with prompt notice of such requirement(s). Such Party also agrees, to the extent legally permissible, to provide the other Parties, in advance of any such
disclosure, with a list of any Confidential Information it intends to disclose (and, if applicable, the text of the disclosure language itself) and to cooperate with the other Parties to the extent they may seek to limit such disclosure, including,
if requested, taking all reasonable steps to resist or avoid any such judicial or administrative proceeding referred to above. If, in the absence of a protective order or the receipt of a waiver from the other Parties after a request in writing
therefor is made by such Party (such request to be made as soon as practicable to allow the other Parties a reasonable amount of time to respond thereto), such Party or any of its Affiliates is legally required to disclose the Confidential
Information to any tribunal to avoid censure or penalty, such Party may disclose such information without liability hereunder. 
 22.02.3 No Party shall issue or publish any press release or other public communication about Corporation or its business without the express written consent of the other Party, except to the extent such public communication is required by
applicable law or by the rules of any securities exchange; provided that, to the extent practicable, such Party shall provide notice to and consult with the other Party on the content of such communication.” 
 2.14 Expansion of Business 
 Paragraph 22.19 of the Shareholders’ Agreement is amended by replacing the phrase “Amgen or Kirin” with the phrase “any of the Parties”. 
  

	3.	REPRESENTATIONS AND WARRANTIES 

 3.01
Representations and Warranties of Kirin Holdings and Kirin Pharma 
 To induce Amgen to enter into and perform this
Agreement, Kirin Holdings and Kirin Pharma (collectively, the “Kirin Parties”), jointly and severally, represent and warrant to Amgen as of the date hereof as follows: 
 (a) Kirin Pharma is a corporation duly organized and validly existing and in good standing under the laws of the country of Japan and has
all requisite power and authority to 

  

 16 

 
lawfully carry on its business as now being conducted and to make, execute, deliver and perform this Amendment Agreement. All of the outstanding Equity
Securities of Kirin Pharma are held of record and beneficially by Kirin Holdings. 
 (b) This Amendment Agreement has
been duly authorized and has been approved by all necessary corporate action of each Kirin Party. This Amendment Agreement has been duly executed and delivered by each Kirin Party and constitutes a valid and legally binding obligation of each Kirin
Party, enforceable against each Kirin Party in accordance with its terms. 
 (c) Neither execution or delivery of this
Amendment Agreement nor its performance by each Kirin Party will, with or without notice, lapse of time or both, (i) conflict with, violate or result in a breach of any term, condition or provision of, nor constitute a material default under,
or result in the acceleration of any material obligation under, or permit the termination of any indenture, material contract or other material agreement to which a Kirin Party is a party or by which a Kirin Party or its properties is subject or
bound; (ii) conflict with or violate the provisions of any judgment, decree or order to which such Kirin Party is subject or such Kirin Party’s registry certificate, articles of association or comparable governing documents, or to the best
of each Kirin Party’s knowledge, any law or regulation; or (iii) result in the creation or acceleration of any obligations under any lien, charge, pledge, security interest, claim or other encumbrance on any of the assets of any Kirin
Party or any of its subsidiaries. 
 (d) Neither Kirin Party is a party to any pending or threatened suit, action or legal,
administrative, arbitration or other proceeding which might materially and adversely affect the transactions contemplated by this Amendment Agreement, nor does either Kirin Party know of any facts which are likely with the passage of time to give
rise to such a suit, action or proceeding. 
 (e) No notices, reports or filings are required to be made by any Kirin Party
with, nor are any consents, registrations, approvals, permits or authorizations required to be obtained by any Kirin Party from, any domestic or foreign governmental or regulatory authority, agency, commission, body, court or other legislative,
executive or judicial governmental entity (each, a “Governmental Entity”), in connection with the execution, delivery and performance of this Amendment Agreement by any of the parties hereto. 
 (f) Kirin Holdings and Kirin Pharma have provided Amgen with the documentation listed on Appendix D to this Agreement (the
“Reorganization Package”), pertaining to the Reorganization and the assignment, conveyance and transfer of the rights and obligations of Kirin Holdings under each Kirin/Amgen Agreement. The documentation comprising the
Reorganization Package is true, accurate and complete, and describes the Reorganization in all material respects. The Reorganization Package does not contain any untrue statement of a material fact, or omit to state a material fact necessary to make
the statements or facts contained herein or therein not misleading. The Reorganization will be effected in accordance with the Reorganization Package. 
 3.02 Representations and Warranties of Amgen 
 To induce the Kirin Parties to enter
into this Agreement, Amgen represents and 

  

 17 

 
warrants to Kirin Holdings and Kirin Pharma as of the date hereof as follows: 
 (a) This Amendment Agreement has been duly authorized and has been approved by all necessary corporate action of Amgen. This Amendment
Agreement has been duly executed and delivered and constitutes a valid and legally binding obligation of Amgen, enforceable against Amgen in accordance with its terms. 
 (b) Neither execution or delivery of this Amendment Agreement nor its performance by Amgen will, with or without notice, lapse of time or
both, (i) conflict with, violate or result in a breach of any term, condition or provision of, nor constitute a material default under, or result in the acceleration of any material obligation under, or permit the termination of any indenture,
material contract or other material agreement to which Amgen is a party or by which Amgen or its properties is subject or bound; (ii) conflict with or violate the provisions of any judgment, decree or order to which Amgen is subject or
Amgen’s certificate of incorporation, bylaws or comparable governing documents, or to the best of Amgen’s knowledge, any law or regulation; or (iii) result in the creation or acceleration of any obligations under any lien, charge,
pledge, security interest, claim or other encumbrance on any of the assets of Amgen or any of its subsidiaries. 
 (c) Amgen
is not a party to any pending or threatened suit, action or legal, administrative, arbitration or other proceeding which might materially and adversely affect the transactions contemplated by this Amendment Agreement, nor does Amgen know of any
facts which are likely with the passage of time to give rise to such a suit, action or proceeding. 
 (d) No notices, reports
or filings are required to be made by Amgen with, nor are any consents, registrations, approvals, permits or authorizations required to be obtained by Amgen from a Governmental Entity, in connection with the execution, delivery and performance of
this Amendment Agreement by any of the parties hereto. 
  

	4.	GUARANTEE 

 Notwithstanding the
provisions of any other document, agreement or instrument (including but not limited to the Corporate Split Agreement between Kirin Holdings and Kirin Pharma), the provisions of the Shareholders’ Agreement, as amended by this Amendment
Agreement, shall remain binding upon Kirin Holdings and Kirin Holdings shall not be released or discharged from any obligations in respect thereof. Notwithstanding the provisions of any other document, agreement or instrument, Kirin Holdings hereby
absolutely, unconditionally and irrevocably guarantees to Amgen, as a primary obligor and not merely as a surety, the due and punctual performance and observance of, and compliance with, all covenants, agreements, obligations, liabilities,
representations and warranties of Kirin Pharma under or pursuant to the Shareholders’ Agreement, each Kirin/Amgen Agreement and this Amendment Agreement, as each such agreement may be amended or modified from time to time with or without notice
to Kirin Holdings (all such obligations being collectively referred to as the “Guaranteed Obligations”). Amgen shall provide reasonable written notice to Kirin Holdings if Kirin Pharma fails to perform the Guaranteed Obligations
when due. Kirin Holdings irrevocably and unconditionally waives, and agrees that its liability under this representation shall be unaffected by, any act, omission, delay or other circumstance or election of remedies by Amgen that might 

  

 18 

 
otherwise constitute a legal or equitable discharge or defense of a guarantor or surety. Kirin Holdings further agrees that its guarantee is a continuing
guarantee of payment and performance of the Guaranteed Obligations when due (whether or not any bankruptcy, insolvency or similar proceeding under applicable law shall have stayed the accrual or collection of any of the Guaranteed Obligations or
operated as a discharge thereof) and not of collection. The foregoing guarantee shall [*] (a) as of the consummation of any transaction providing for a Purchase Event, if and only if Kirin Holdings [*] such transaction or (b) after the [*]
that Kirin-Amgen [*] the agreements between Kirin-Amgen, on the one hand, and Kirin Holdings and/or Kirin Pharma, on the other hand, including all of such Kirin/Amgen Agreements, in accordance with Section 17.03 of the Shareholders Agreement,
except that, in any such case of (a) or (b), no such [*] shall [*] Kirin Holdings from [*] with respect to any Guaranteed Obligations that [*] to such [*]. 
  

	5.	MISCELLANEOUS 

 5.01 No Further Amendment

 Except as expressly set forth in this Amendment Agreement, from and after the effective time of the Reorganization, all the
terms and conditions of the Shareholders’ Agreement and each Kirin/Amgen Agreement shall remain unchanged and in full force and effect and shall continue to be binding between or among Kirin Pharma, Kirin Holdings and either or both of Amgen
and Kirin-Amgen, as the case may be. 
 5.02 Entire Agreement; Amendment 
 This Amendment Agreement (together with its Appendices and all documents and instruments delivered in connection herewith) constitutes the
full and complete agreement and understanding between the parties hereto and shall supersede any and all prior written and oral agreements concerning the subject matter contained herein. This Amendment Agreement may not be modified or amended, nor
may any provision hereof be waived without a written instrument executed by the parties hereto. 
 5.03 Waiver 
 No failure or delay by any Party to insist upon the strict performance of any term, condition, covenant or agreement of this Amendment
Agreement, or to exercise any right, power or remedy hereunder or thereunder or consequent upon a breach hereof or thereof shall constitute a waiver of any such term, condition, covenant, agreement, right, power or remedy or of any such breach or
preclude such Party from exercising any such right, power or remedy at any later time or times. 
 5.04 Remedies 
 No right, power or remedy herein conferred upon or reserved to any Party is intended to be exclusive of any other right, power or remedy
or remedies, and each and every right, power and remedy of any Party pursuant to this Amendment Agreement or now or hereafter existing at law or in equity or by statute or otherwise shall to the extent permitted by law be cumulative and concurrent,
and shall be in addition to every other right, power or remedy pursuant to this Amendment Agreement, or now or hereafter existing at law or in equity or by 

  

 19 

 
statute or otherwise and the exercise or beginning of the exercise by any Party of any one or more of such rights, powers or remedies shall not preclude the
simultaneous or later exercise by any Party of any or all such other rights, powers or remedies. 
 5.05 Headings 
 Headings in this Amendment Agreement are included herein for the convenience of reference only and shall not constitute a part of this
Amendment Agreement for any purpose. 
 5.06 Effectiveness 
 Any provision of this Amendment Agreement which is prohibited or unenforceable in any jurisdiction shall as to such jurisdiction be
ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof or effecting the validity or enforceability of such provision in any other jurisdiction. 
 5.07 Governing Law 
 This Amendment Agreement, other than the provision contained in the first paragraph of Section 1.03, shall be construed in accordance with the internal laws, and not the law of conflicts, of the State of California applicable to
agreements made and to be performed in such state. 
 5.08 Binding Effect 
 This Amendment Agreement shall be binding upon and inure to the benefit of the parties hereto, their successors and assigns. 

5.09 Number and Gender 
 Words in the singular shall include the plural, and words in a particular gender shall include either or both additional genders, when the context in which such words are used indicates that such is the intent. 
 5.10 Counterparts 
 This Amendment Agreement may be executed in one or more counterparts by the parties hereto. All counterparts shall be construed together and shall constitute one agreement. 
 5.11 Validity 
 If for
any reason any clause or provision of this Amendment Agreement, or the application of any such clause or provision in a particular context or to a particular situation, circumstance or person, should be held unenforceable, invalid or in violation of
law by any court or other tribunal, then the application of such clause or provision in contexts or to situations, circumstances or persons other than that in or to which it is held unenforceable, invalid or in violation of law shall not be affected
thereby, and the remaining clauses and provisions hereof shall nevertheless remain in full force and effect. 
  

 20 

 5.12 Confidentiality 
 (a) Each Party agrees not to, and agrees to cause such Party’s directors, officers, employees, etc. not to, disclose or permit the
disclosure to any third party of any confidential, non-public or proprietary information relating to this Amendment Agreement (collectively, “Amendment Confidential Information”); provided that such disclosure may be made
(i) with the prior written consent of Kirin Holdings and Amgen, (ii) to any Person who is a director, officer, employee, attorney, consultant or accountant of a Party who needs to know such information for the purposes of this Amendment
Agreement, and agrees to be bound by such Party’s obligation hereunder, (iii) subject to Paragraph 5.12(b), pursuant to a subpoena or order issued by a court, arbitrator or governmental body, agency or official, (iv) subject to
Paragraph 5.12(c), to the extent required by applicable law or by the rules of any securities exchange or (v) to any Person, who agrees in writing, for the benefit of the nondisclosing Parties, to comply with this Section 5.12, in
connection with a due diligence investigation undertaken by such Person in connection with a merger, consolidation or Share Exchange with the disclosing Party, or a purchase of a material portion of the assets or the business (including corporate
split) of the disclosing Party. 
 (b) In the event that a Party or any of its Affiliates is required to disclose any
Amendment Confidential Information in connection with any judicial or administrative proceedings (by oral questions, interrogatories, requests for information or documents, subpoena, civil investigation demand or similar process), that Party in
advance of such disclosure shall provide the other Parties with prompt notice of such requirement(s). Such Party also agrees, to the extent legally permissible, to provide the other Parties, in advance of any such disclosure, with a list of any
Amendment Confidential Information it intends to disclose (and, if applicable, the text of the disclosure language itself) and to cooperate with the other Parties to the extent they may seek to limit such disclosure, including, if requested, taking
all reasonable steps to resist or avoid any such judicial or administrative proceeding referred to above. If, in the absence of a protective order or the receipt of a waiver from the other Parties after a request in writing therefor is made by such
Party (such request to be made as soon as practicable to allow the other Parties a reasonable amount of time to respond thereto), such Party or any of its Affiliates is legally required to disclose the Amendment Confidential Information to any
tribunal to avoid censure or penalty, such Party may disclose such information without liability hereunder. 
 (c) No Party
shall issue or publish any press release or other public communication concerning this Amendment Agreement without the express written consent of the other Parties, except to the extent such public communication is required by applicable law or by
the rules of any securities exchange; provided that, to the extent practicable, such Party shall provide notice to and consult with the other Parties on the content of such communication. Kirin Holdings, Kirin Pharma and Kirin-Amgen hereby
acknowledge and agree that Amgen shall have the right to file an unredacted copy of this Amendment Agreement with the U.S. Securities and Exchange Commission. 
  

 21 

 IN WITNESS WHEREOF, the undersigned have caused this Amendment Agreement to be executed by their duly
authorized representatives in the manner legally binding upon them. 
  

					
	KIRIN BREWERY COMPANY, LIMITED
		
	By	 	/s/ Kazuyasu Kato
		 	Name:	 	Kazuyasu Kato
		 	Title:	 	President, Representative Director
		 	Date:	 	June 28, 2007
	
	KIRIN PHARMA COMPANY, LIMITED
		
	By	 	/s/ Katsuhiko Asano
		 	Name:	 	Katsuhiko Asano, Ph.D
		 	Title:	 	President, Representative Director
		 	Date:	 	June 28, 2007
	
	AMGEN INC.,
	a Delaware corporation
		
	By	 	/s/ George J. Morrow
		 	Name:	 	George J. Morrow
		 	Title:	 	Executive Vice President, Global
		 	Commercial Operations
		 	Date:	 	June 28, 2007
	
	KIRIN-AMGEN, INC.,
	a Delaware corporation
		
	By	 	/s/ Dominique Monnet
		 	Name:	 	Dominique Monnet
		 	Title:	 	President
		 	Date:	 	June 28, 2007

 Appendix A 
 Kirin/Amgen Agreements 
 [*] 
  

 A-1 

 Appendix B 
 Restated Charter 

 Appendix C 
 Asian Countries 
 [*] 
  

 C-1 

 Appendix D 
 Reorganization Package 
 [*] 
  

 D-1Purchase Agreement, dated May 24, 2007

 Exhibit 10.76 
 EXECUTION COPY 

 PURCHASE AGREEMENT 
 Dated May 24, 2007 
 between 
 AMGEN INC. 
 and 
 MORGAN STANLEY & CO.
INCORPORATED 
 and 
 MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED 
 and 
 THE INITIAL PURCHASERS NAMED IN SCHEDULE A HEREOF 
  

 AMGEN INC. 
 $2,000,000,000 SENIOR FLOATING RATE NOTES DUE 2008 
 $1,100,000,000 5.85% SENIOR NOTES DUE 2017 

$900,000,000 6.375% SENIOR NOTES DUE 2037 
 PURCHASE AGREEMENT 
 Dated May 24, 2007 
 Morgan
Stanley & Co. Incorporated 
 Merrill Lynch, Pierce, Fenner & Smith Incorporated 
 c/o Morgan Stanley & Co. Incorporated 
 1585 Broadway
New York, 
 New York 10036 
 Dear Sirs and
Mesdames: 
 Amgen Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several purchasers named
in Schedule A hereto (the “Initial Purchasers”) $2,000,000,000 aggregate principal amount of its Senior Floating Rate Notes due 2008 (the “Floating Rate Notes”), $1,100,000,000 aggregate principal amount of its
5.85% Senior Notes due 2017 (the “2017 Notes”) and $900,000,000 aggregate principal amount of its 6.375% Senior Notes due 2037 (the “2037 Notes” and, together with the Floating Rate Notes and the 2017 Notes, the
“Securities”) to be issued pursuant to the provisions of an Indenture, dated as of August 4, 2003 (the “Indenture”), between the Company and The Bank of New York, as successor to JPMorgan Chase Bank, N.A., as
trustee (the “Trustee”). 
 Pursuant to the transactions contemplated by this Agreement, the Securities will be offered and
sold to the Initial Purchasers and reoffered by the Initial Purchasers without being registered under the Securities Act of 1933, as amended (the “Securities Act”), to qualified institutional buyers in compliance with the exemption
from registration provided by Rule 144A under the Securities Act and in offshore transactions in reliance on Regulation S under the Securities Act (“Regulation S”). 
 The Initial Purchasers and their direct and indirect transferees (“Subsequent Purchasers”) will be entitled to the benefits of a
Registration Rights Agreement, to be dated as of May 30, 2007 between the Company and Morgan Stanley & Co. Incorporated (“Morgan Stanley”) and Merrill Lynch, Pierce, Fenner & Smith Incorporated
(“Merrill Lynch”) on behalf of the Initial Purchasers (the “Registration Rights Agreement”), substantially in the form set forth in Exhibit A. 
  

 1 

 In connection with the offering of the Securities, the Company has prepared a preliminary offering
memorandum dated May 23, 2007 (the “Preliminary Memorandum”) and will prepare a final offering memorandum dated May 24, 2007 (the “Final Memorandum” and, together with the Preliminary Memorandum, each a
“Memorandum”) including or incorporating by reference a description of the terms of the Securities, the terms of the offering and a description of the Company. 
 As used herein, the term “Memorandum” shall include in each case the documents incorporated by reference therein. The terms
“supplement,” “amendment” and “amend” as used herein with respect to a Memorandum shall include all documents deemed to be incorporated by reference in the Preliminary Memorandum or Final Memorandum
that are filed subsequent to the date of such Memorandum with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
“Memorandum” means, with respect to any date or time referred to in this Agreement, the most recent memorandum (whether the Final Memorandum, or any amendment or supplement to such document), including exhibits thereto and any
documents incorporated by reference therein, that has been prepared and delivered by the Company to the Initial Purchasers in connection with their solicitation of, purchase of, or offering of, the Securities. 
 1. Representations and Warranties. (a) The Company represents and warrants to, and agrees with, you that as of the date hereof and as of the
Closing Date: 
 (i) As of the Applicable Time (as defined below), neither (x) the Preliminary Memorandum as of the Applicable Time as
supplemented by the final pricing term sheet, in the form attached hereto as Schedule B (the “Pricing Supplement”), that has been prepared and delivered by the Company to the Initial Purchasers in connection with their solicitation
of offers to purchase Securities, all considered together (collectively, the “Disclosure Package”), nor (y) any individual Supplemental Offering Materials (as defined below), when considered together with the Disclosure
Package, included any untrue statement of a material fact or omitted to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. “Applicable
Time” means 2:20 pm (Eastern time) on May 24, 2007 or such other time as agreed by the Company and Morgan Stanley. 
 “Supplemental Offering Materials” means any “written communication” (within the meaning of the Securities Act and the rules and regulations thereunder (the “1933 Act Regulations”)) prepared by or
on behalf of the Company, or used or referred to by the Company, that constitutes an offer to sell or a solicitation of an offer to buy the Securities other than the Memorandum or amendments or supplements thereto (including the Pricing Supplement),
including, without limitation, any road show relating to the Securities that constitutes such a written communication. The Company and each Initial Purchaser agree that no offering of the Securities will be made by the Company or any Initial
Purchaser with any “written communication” (within the meaning of the 1933 Act Regulations other than such Supplemental Offering Materials) without the prior written agreement of the Company and Morgan Stanley and Merrill Lynch, other than
as disclosed to the Company; provided, however, that prior to the preparation of the Pricing Supplement, the Initial Purchasers are authorized to use the information to be set forth in the Pricing Supplement in communications conveying
information relating to the offering to potential investors. 
  

 2 

 As of its issue date and as of the Closing Date, the Final Memorandum will not include an untrue
statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. 
 The representation and warranties in this subsection shall not apply to statements in or omissions from the Disclosure Package or the Final Memorandum
made in reliance upon and in conformity with written information furnished to the Company by any Initial Purchaser expressly for use therein. 
 (ii) The Memorandum as delivered from time to time shall incorporate by reference the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006; the Company’s Quarterly Report on Form 10-Q for the
quarterly period ended March 31, 2007 and the Company’s Current Reports on Form 8-K filed with the Commission on January 19, 2007, February 20, 2007, March 2, 2007, March 12, 2007, April 12,
2007, May 15, 2007, May 21, 2007, May 22, 2007 and May 23, 2007. The documents incorporated or deemed to be incorporated by reference in the Memorandum at the time they were or hereafter are filed, or, if amended,
as so amended, with the Commission complied and, with respect to future filings, will comply, in all material respects with the requirements of the Exchange Act and the rules and regulations of the Commission thereunder, and, when read together with
the other information in the Memorandum, at the date of the Memorandum and at the Closing Date, will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances in which they were made, not misleading. 
 (iii) Ernst & Young, LLP, which has
audited certain consolidated financial statements of the Company and its consolidated subsidiaries to be incorporated by reference in the Memorandum, are independent registered public accountants with respect to the Company and its subsidiaries
within the meaning of Regulation S-X under the Securities Act and the 1933 Act Regulations. 
 (iv) The consolidated financial statements
included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2007, which is incorporated by reference
in the Disclosure Package and Final Memorandum present fairly, in all material respects, the financial position of the Company and its consolidated subsidiaries at December 31, 2006 and 2005, and at March 31, 2007 and 2006, respectively,
and the statements of operations and cash flows of the Company and its consolidated subsidiaries for each of the three years in the period ended December 31, 2006, and for each of the three months ended March 31, 2007 and 2006,
respectively, in conformity with accounting principles generally accepted in the United States (“GAAP”). The related financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a
whole, present fairly in all material respects the information set forth therein. 
  

 3 

 (v) Since the respective dates as of which information is given in the Disclosure Package and Final
Memorandum, except as otherwise stated therein, (A) there has been no material adverse change in the financial condition or in the earnings of the Company and its subsidiaries considered as one enterprise, (B) there have been no
transactions entered into by the Company or any of its subsidiaries, other than those in the ordinary course of business, which are material with respect to the Company and its subsidiaries considered as one enterprise, and (C) there has been
no dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock not described in the Final Memorandum. 
 (vi) Each of the Company, Amgen Manufacturing, Limited, a Bermuda corporation (“Amgen Manufacturing”), and Immunex Corporation, a Washington corporation (“Immunex” and, together with
Amgen Manufacturing, the “Significant Subsidiaries”), has been duly incorporated or organized and is validly existing in good standing under the laws of the jurisdiction in which it is incorporated, chartered or organized with the
corporate power and authority to own or lease, as the case may be, and to operate its properties and conduct its business as described in the Disclosure Package and Final Memorandum and is duly qualified to do business as a foreign corporation or
organization and is in good standing under the laws of each jurisdiction which requires such qualification, except, in each case, where the failure so to qualify or to be in good standing would not have a material adverse effect on the financial
condition of the Company and its subsidiaries, considered as one enterprise (a “Material Adverse Effect”). 
 (vii) All the
issued and outstanding shares of capital stock of the Significant Subsidiaries have been duly and validly authorized and issued and are fully paid and nonassessable, and, except as may be otherwise set forth in the Disclosure Package and the Final
Memorandum, all outstanding shares of capital stock of the Significant Subsidiaries are owned by the Company either directly or through a wholly-owned subsidiary free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or
equity; none of the outstanding shares of capital stock of the Significant Subsidiaries was issued in violation of the preemptive or similar rights of any securityholder of either Significant Subsidiary. 
 (viii) Neither of the Significant Subsidiaries is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any
other distribution on such subsidiary’s capital stock, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary’s property or assets to the Company or any other
subsidiary of the Company, except as may be described in or contemplated by the Disclosure Package and the Final Memorandum and except as would not result in a Material Adverse Effect. 
 (ix) The unaudited consolidated capitalization of the Company as of December 31, 2006 is as set forth in the Disclosure Package and the Final
Memorandum in the column entitled “Actual” under the caption “Capitalization.” The outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and nonassessable; none of
the outstanding shares of capital stock of the Company was issued in violation of the preemptive or similar rights of any security holder of the Company. 
  

 4 

 (x) This Agreement has been duly authorized, executed and delivered by the Company. 
 (xi) The Indenture has been duly authorized, executed and delivered by the Company, and, assuming the due authorization, execution and delivery of the
Indenture by the Trustee, is a valid and binding agreement of the Company enforceable against the Company in accordance with its terms, except (A) to the extent that a waiver of rights under any usury laws may be unenforceable and as the
enforceability thereof may be limited by bankruptcy, insolvency, fraudulent conveyance, moratorium or other similar laws now or hereafter in effect relating to or affecting the enforcement of creditors’ rights and remedies generally and
(B) as rights of acceleration and the availability of equitable remedies may be limited by equitable principles of general applicability, whether or not enforcement is sought at law or in equity. 
 (xii) At the Closing Date, the Registration Rights Agreement will have been duly authorized by the Company and, when executed and delivered by the
Company, assuming the due authorization, execution and delivery of the Registration Rights Agreement by the Initial Purchasers, will constitute a valid and binding agreement of the Company, enforceable against the Company in accordance with its
terms, except (A) as the enforceability thereof may be limited by bankruptcy, insolvency, fraudulent conveyance, moratorium or other similar laws now or hereafter in effect relating to or affecting the enforcement of creditors’ rights and
remedies generally, (B) as rights of acceleration and the availability of equitable remedies may be limited by equitable principles of general applicability, whether or not enforcement is sought at law or in equity and (C) as rights to
indemnification or contribution may be limited by federal or state securities laws or public policy considerations. 
 (xiii) The Securities
have been duly authorized by the Company, and, at the Closing Date, the Securities will have been duly executed by the Company and, when authenticated, issued and delivered in the manner provided for in the Indenture and delivered against payment of
the Purchase Price (as defined below) therefore as provided in this Agreement, will be the valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, except (A) to the extent that a waiver of
rights under any usury laws may be unenforceable and as the enforceability thereof may be limited by bankruptcy, insolvency, fraudulent conveyance, moratorium or other similar laws now or hereafter in effect relating to or affecting the enforcement
of creditors’ rights and remedies generally and (B) as rights of acceleration and the availability of equitable remedies may be limited by equitable principles of general applicability, whether or not enforcement is sought at law or in
equity. At the Closing Date, the Securities will be in the form contemplated by, and will be entitled to the benefits of, the Indenture and the Registration Rights Agreement. 
 (xiv) The Securities, the Indenture and the Registration Rights Agreement will conform in all material respects to the respective statements relating
thereto contained in the Memorandum. 
 (xv) Neither the Company nor any of its Significant Subsidiaries is in violation of its charter or
by-laws or in default in the performance or observance of any obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which
the 

  

 5 

 
Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of the property or assets of the Company or any of
its subsidiaries is subject, except for such defaults that would not result in a Material Adverse Effect. 
 (xvi) The execution, delivery
and performance by the Company of its obligations under this Agreement, the Indenture, the Registration Rights Agreement and the Securities will not contravene any provision of (A) the Amended and Restated Certificate of Incorporation, or
Amended and Restated Bylaws of the Company, (B) any agreement or other instrument binding upon the Company or its business or assets that is material to the financial condition of the Company and its subsidiaries, considered as one enterprise,
(C) applicable law and (D) any judgment, order, decree of any governmental body, agency or court having jurisdiction over the Company or its business or assets. 
 (xvii) Except as disclosed in the Disclosure Package and the Final Memorandum, there is no action, suit, proceeding, inquiry or investigation before or brought by any court or governmental agency or body, domestic or
foreign, now pending, or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries which might reasonably be expected to result in a Material Adverse Effect, or which might reasonably be expected to
materially and adversely affect the properties or assets of the Company or any of its subsidiaries or the consummation of the transactions contemplated by this Agreement or the performance by the Company of its obligations hereunder. The aggregate
of all pending legal or governmental proceedings to which the Company or any of its subsidiaries is a party or of which any of their respective property or assets is the subject which are not described in the Disclosure Package and the Final
Memorandum, including ordinary routine litigation incidental to the business, could not reasonably be expected to result in a Material Adverse Effect. 
 (xviii) The Company and its Significant Subsidiaries own or possess, or can acquire on reasonable terms, adequate patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other
unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks and trade names (collectively, “Intellectual Property”) which in each case are material to the financial
condition of the Company and its subsidiaries, considered as one enterprise and, except as described in the Disclosure Package and the Final Memorandum, neither the Company nor any of its Significant Subsidiaries has received any notice of any
infringement of or conflict with asserted rights of others with respect to any Intellectual Property, which infringement or conflict, singly or in the aggregate, could reasonably be expected to result in a Material Adverse Effect. 
 (xix) No consent, approval, authorization or order of or qualification with any governmental body or agency is required for the performance by the
Company of its obligations under this Agreement, the Indenture or in connection with the offering, issuance and sale of the Securities, except (A) such as have been already obtained or will have been obtained prior to the Closing Date and
(B) as may be required under the 1933 Act Regulations, the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”), and the Rules and Regulations thereunder, in each case with respect to transactions contemplated by
the Registrations Rights Agreement and the Indenture. 
  

 6 

 (xx) The Company has all necessary consents, authorizations, approvals, orders, certificates and permits
of and from (collectively, “Governmental Permits”), and has made all declarations and filings with, all federal, state, local and other governmental authorities, all self-regulatory organizations and all courts and other tribunals,
to own, lease, license and use its properties and assets and to conduct its business in the manner described in the Disclosure Package and the Final Memorandum, except to the extent that the failure to obtain or file would not have a Material
Adverse Effect; and the Company has not received any notice of proceedings relating to the revocation or modification of any such Governmental Permits which, singly or in the aggregate, could reasonably be expected to result in a Material Adverse
Effect. 
 (xxi) Except as described in the Disclosure Package and the Final Memorandum and except as would not, singly or in the aggregate,
result in a Material Adverse Effect, (A) neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or
administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water,
groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances,
petroleum or petroleum products (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively,
“Environmental Laws”), (B) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements, (C) there are
no pending or threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigations or proceedings relating to any Environmental Law against the Company or any
of its subsidiaries and (D) there are no events or circumstances that might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or agency,
against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws. 
 (xxii) Neither the
Company nor any of its subsidiaries is in violation of any Federal or state law or regulation relating to occupational safety and health or to the storage, handling and transportation of hazardous or toxic materials; the Company and each of its
subsidiaries have received all permits, licenses or other approvals required of them under applicable Federal and state occupational safety and health laws and Environmental Laws and regulations to conduct their respective businesses, and the
Company and each such subsidiary is in compliance with all terms and conditions of any such permit, license or approval, except any such violation of law or regulation, failure to receive required permits, licenses or other approvals or failure to
comply with the terms and conditions of such permits, licenses or approvals that would not, singly or in the aggregate, result in a Material Adverse Effect, except as described in or contemplated by the Disclosure Package and the Final Memorandum.

 (xxiii) The Company and its subsidiaries, taken as a whole, maintain a system of internal accounting controls sufficient to provide
reasonable assurances that (A)

  

 7 

 
transactions are executed in accordance with management’s general or specific authorization; (B) transactions are recorded as necessary to permit
preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C) access to assets is permitted only in accordance with management’s general or specific authorization; and (D) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. 
 (xxiv) The Company is not, and after giving effect to the offering and sale of the Securities and the application of the proceeds thereof as described in the Disclosure Package and Final Memorandum, will not be an
“investment company,” or an entity “controlled” by an investment company, as such terms are defined in the Investment Company Act of 1940, as amended. 
 (xxv) The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are reasonable and consistent with sound business
practice. 
 (xxvi) Neither the Company nor any of its affiliates, as such term is defined in Rule 501(b) of Regulation D under the
Securities Act (each, an “Affiliate”), has, directly or indirectly, solicited any offer to buy, sold or offered to sell or otherwise negotiated in respect of, or will solicit any offer to buy or offer to sell or otherwise negotiate
in respect of, any security (as defined in the Securities Act) that is or would be integrated with the sale of the Securities in a manner that would require the Securities to be registered under the Securities Act. 
 (xxvii) The Securities are eligible for resale pursuant to Rule 144A under the Securities Act and will not be, at the Closing Date, of the same class as
securities listed on a national securities exchange registered under Section 6 of the Exchange Act, or quoted in a U.S. automated interdealer quotation system. 
 (xxviii) None of the Company, any of its Affiliates or any person acting on its or any of their behalf (other than the Initial Purchasers and their Affiliates, as to whom the Company makes no representation) has
engaged or will engage, in connection with the offering of the Securities, in any form of general solicitation or general advertising within the meaning of Rule 502(c) of Regulation D under the Securities Act or in any manner involving a public
offering within the meaning of Section 4(2) of the Securities Act. 
 (xxix) Subject to compliance by the Initial Purchasers with the
representations, warranties and agreements set forth in Section 7, it is not necessary in connection with the offer, sale and delivery of the Securities to the Initial Purchasers and to each Subsequent Purchaser in the manner contemplated by
this Agreement and the Disclosure Package and Final Memorandum to register the Securities under the Securities Act. 
 (xxx) The Company is
subject to the reporting requirements of Section 13 or Section 15(d) of the Exchange Act. 
 (xxxi) With respect to those
Securities sold in reliance on Regulation S, (A) none of the Company, its Affiliates or any person acting on its or their behalf (other than the Initial Purchasers and their Affiliates, as to whom the Company makes no representation) has

  

 8 

 
engaged or will engage in any directed selling efforts within the meaning of Regulation S and (B) each of the Company and its Affiliates and any person
acting on its or their behalf (other than the Initial Purchasers and their Affiliates, as to whom the Company makes no representation) has complied and will comply with the offering restrictions requirement of Regulation S. 
 (xxxii) There are no persons with registration rights or other similar rights to have any securities included in any registration statement filed
pursuant to a registration agreement or in any offering made pursuant to such registration statement, other than pursuant to that certain Registration Rights Agreement, dated as of February 17, 2006, between the Company, Merrill Lynch, Pierce,
Fenner & Smith, Incorporated and Morgan Stanley & Co. Incorporated. 
 (b) Officer’s Certificate. Any
certificate signed by any officer of the Company and delivered to the Initial Purchasers or counsel for the Initial Purchasers in connection with the issuance of the Securities shall be deemed a representation and warranty by the Company, as to
matters covered thereby, to the Initial Purchasers. 
 2. Agreements to Sell and Purchase. 
 (a) The Company hereby agrees to sell to the several Initial Purchasers, and each Initial Purchaser, upon the basis of the representations and warranties
herein contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to purchase from the Company the respective principal amount of Securities set forth opposite its name in Schedule A hereto and the Company and
the Initial Purchasers agree that the Company shall receive 99.85% of the aggregate principal amount of the Floating Rate Notes, 99.393% of the aggregate principal amount of the 2017 Notes and 99.018% of the aggregate principal amount of the 2037
Notes, plus accrued interest, in each case, if any, from the Closing Date. 
 The Company hereby agrees that, without the prior written
consent of Morgan Stanley on behalf of the Initial Purchasers, it will not, during the period beginning on the date of this Agreement and continuing to and including the Closing Date, offer, sell, contract to sell or otherwise dispose of any debt of
the Company or warrants to purchase debt of the Company substantially similar to the Securities (other than the sale of the Securities under this Agreement). 
 3. Terms of Offering. You have advised the Company that the Initial Purchasers will make an offering of the Securities purchased by the Initial Purchasers hereunder on the terms to be set forth in the
Disclosure Package and the Final Memorandum, as soon as practicable after this Agreement is entered into as in your reasonable judgment is advisable and that it is the intention of the Initial Purchasers not to hold any Securities after the Closing
Date. 
 4. Payment and Delivery. Payment for the Securities shall be made to the Company in Federal or other funds immediately
available in New York City against delivery of such Securities for the respective accounts of the several Initial Purchasers at 10:00 a.m., New York City time, on May 30, 2007, or at such other time on the same or such other date as shall be
agreed by the parties. The time and date of such payment are hereinafter referred to as the “Closing Date.” 
  

 9 

 Certificates for the Securities, if any, shall be in global form and registered in the name of
Cede & Co., as nominee of the Depository Trust Company. The certificates evidencing the Securities shall be delivered to the Trustee on the Closing Date for the respective accounts of the several Initial Purchasers, with any transfer taxes
payable in connection with the transfer of the Securities to the Initial Purchasers duly paid, against payment of the Purchase Price therefor plus accrued interest, if any, to the date of payment and delivery. 
 5. Conditions to the Initial Purchasers’ Obligations. The several obligations of the Initial Purchasers to purchase and pay for the
Securities on the Closing Date are subject to the following conditions: 
 (a) Subsequent to the execution and delivery of this Agreement and
prior to the Closing Date: 
 (i) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or
potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded of any of the Company’s securities by any “nationally recognized statistical rating
organization,” as such term is defined for purposes of Rule 436(g)(2) under the Securities Act; and 
 (ii) there shall not have been,
since the date of this Agreement or since the respective dates as of which information is given in the Disclosure Package and Final Memorandum, any material adverse change in the financial condition or in the earnings of the Company and its
subsidiaries, taken as a whole. 
 (b) The Initial Purchasers shall have received on the Closing Date, a certificate, dated as of the Closing
Date and signed by the chief executive officer or the chief financial officer of the Company, to the effect set forth in Section 5(a)(i) and to the effect that (i) the representations and warranties of the Company contained in this
Agreement are true and correct in all material respects as of the Closing Date and (ii) the Company has complied in all material respects with all of the agreements and satisfied in all material respects all of the conditions on its part to be
performed or satisfied hereunder on or before the Closing Date. 
 The officer signing and delivering such certificate may rely upon the best
of his or her knowledge as to proceedings threatened. 
 (c) The Initial Purchasers shall have received on the Closing Date an opinion or
opinions and a negative assurances letter of Latham & Watkins LLP, outside counsel for the Company, dated the Closing Date, substantially in the forms set forth in Exhibit B. 
 (d) The Initial Purchasers shall have received on the Closing Date an opinion of the Company’s general counsel or any assistant general counsel,
dated the Closing Date, substantially in the form set forth in Exhibit C. 
 (e) The Initial Purchasers shall have received on the Closing
Date, an opinion of Shearman & Sterling LLP, counsel for the Initial Purchasers, dated the Closing Date, covering the matters set forth in Exhibit D. 
  

 10 

 (f) The Initial Purchasers and the board of directors of the Company shall have received on the date
hereof a letter, dated the date hereof, in form and substance reasonably satisfactory to the Initial Purchasers, from Ernst & Young LLP, independent registered public accountants, containing statements and information of the type ordinarily
included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained in or incorporated by reference into the Disclosure Package and the Final Memorandum and
on the Closing Date, the Initial Purchasers and the board of directors of the Company shall have received a letter from Ernst & Young LLP, in form and substance reasonably satisfactory to the Initial Purchasers, to the effect that they
reaffirm the statements made in the letter dated the date hereof. 
 6. Covenants of the Company. In further consideration of the
agreements of the Initial Purchasers contained in this Agreement, the Company covenants with each Initial Purchaser as follows: 
 (a) To
furnish to you in New York City, without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period mentioned in Section 6(c), as many copies of the Final Memorandum, and
any supplements and amendments thereto as you may reasonably request. 
 (b) Before amending or supplementing any Memorandum, to furnish to
you a copy of each such proposed amendment or supplement and not to use any such proposed amendment or supplement to which you reasonably object. 
 (c) If, at any time prior to the completion of the resale of the Securities by the Initial Purchasers, any event shall occur or condition exist as a result of which it is necessary, in the reasonable opinion of the Initial Purchasers or
counsel for the Initial Purchasers, to amend or supplement the Final Memorandum in order to make the statements therein, in the light of the circumstances when the Final Memorandum is delivered to a purchaser, not misleading, or if, in the
reasonable opinion of counsel for the Initial Purchasers, it is necessary to amend or supplement the Final Memorandum to comply with applicable law, forthwith to prepare and furnish, at its own expense, to the Initial Purchasers, either amendments
or supplements to the Final Memorandum so that the statements in the Final Memorandum as so amended or supplemented will not, in the light of the circumstances when the Final Memorandum is delivered to a purchaser, be misleading or so that the Final
Memorandum, as amended or supplemented, will comply with applicable law. 
 (d) To endeavor to qualify the Securities for offer and sale
under the securities or Blue Sky laws of such jurisdictions as you shall reasonably request provided, however, that the Company shall not be required to (i) qualify as a foreign corporation or as a dealer in securities in any
jurisdiction where it would not otherwise be required to qualify but for this Section 6(d), (ii) file any general consent to service of process, (iii) subject itself to taxation in any such jurisdiction if it is not so subject or
(iv) make any changes to its certificate of incorporation or bylaws. 
 (e) Whether or not the transactions contemplated in this
Agreement are consummated or this Agreement is terminated, to pay or cause to be paid all expenses 

  

 11 

 
incident to the performance of its obligations under this Agreement, including: (i) the fees, disbursements and expenses of the Company’s counsel
and the Company’s accountants in connection with the issuance and sale of the Securities and all other fees or expenses of the Company in connection with the preparation of each Memorandum and all amendments and supplements thereto, including
all printing costs associated therewith, and the delivering of copies thereof to the Initial Purchasers, in the quantities herein above specified, (ii) all costs and expenses related to the preparation, issuance and delivery of the Securities
to the Initial Purchasers, including any transfer or other taxes payable thereon, (iii) all expenses in connection with the qualification of the Securities for offer and sale under state securities laws as provided in Section 6(d),
including filing fees and the reasonable fees and disbursements of counsel for the Initial Purchasers in connection with such qualification and in connection with the preparation of any Blue Sky or legal investment memorandum, (iv) any fees
charged by rating agencies for the rating of the Securities, (v) the costs and charges of the Trustee, and (vi) all other cost and expenses incident to the performance of the obligations of the Company hereunder for which provision is not
otherwise made in this Section. It is understood, however, that except as provided in clause (iii) of this Section 6(e), and the last paragraph of Section 10, the Initial Purchasers will pay all of their costs and expenses, including
fees and disbursements of their counsel, transfer taxes payable on resale of any of the Securities by them and any advertising expenses connected with any offers they may make. 
 (f) Not to, and to cause its Affiliates not to, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as
defined in the Securities Act) which could be integrated with the sale of the Securities in a manner which would require the registration under the Securities Act of the Securities. 
 (g) Not to solicit any offer to buy or offer or sell the Securities by means of any form of general solicitation or general advertising (as those terms
are used in Regulation D under the Securities Act) or in any manner involving a public offering within the meaning of Section 4(2) of the Securities Act. 
 (h) While any of the Securities remain “restricted securities” within the meaning of Rule 144(a)(3) of the Securities Act, to make available, upon request, to any seller of such Securities the information
specified in Rule 144A(d)(4) under the Securities Act, unless the Company is then subject to Section 13 or 15(d) of the Exchange Act. 
 (i) Not to, and to cause its Affiliates or any person acting on its or their behalf (other than the Initial Purchasers) not to, engage in any directed selling efforts (as that term is defined in Regulation S) with respect to the Securities,
and the Company and its Affiliates and each person acting on its or their behalf (other than the Initial Purchasers) will comply with the offering restrictions requirement of Regulation S. 
 (j) During the period of two years after the Closing Date, the Company will not, and will not permit any of its affiliates (as defined in Rule 144 under
the Securities Act) to resell any of the Securities which constitute “restricted securities” under Rule 144(a)(3) that have been reacquired by any of them. 
  

 12 

 7. Offering of Securities; Restrictions on Transfer. (a) Each Initial Purchaser, severally
and not jointly, represents and warrants that such Initial Purchaser is a qualified institutional buyer as defined in Rule 144A under the Securities Act (a “QIB”). Each Initial Purchaser, severally and not jointly, agrees with the
Company that (i) it has not and will not solicit offers for, or offer or sell, such Securities by any form of general solicitation or general advertising (as those terms are used in Regulation D under the Securities Act) or in any manner
involving a public offering within the meaning of Section 4(2) of the Securities Act, (ii) it will solicit offers for such Securities only from, and will offer such Securities only to, persons that it reasonably believes to be (A) in
the case of offers inside the United States, QIBs and (B) in the case of offers outside the United States, to persons other than U.S. persons (“Foreign Purchasers,” which term shall include dealers or other professional
fiduciaries in the United States acting on a discretionary basis for foreign beneficial owners (other than an estate or trust)) in reliance upon Regulation S under the Securities Act that, in each case in purchasing such Securities are deemed to
have represented and agreed as provided in the Disclosure Package and the Final Memorandum under the caption “Transfer Restrictions,” and (iii) it will otherwise act in accordance with the terms and conditions set forth in this
Agreement and the Memorandum in connection with the placement of the Securities contemplated hereby. 
 (b) Each Initial Purchaser, severally
and not jointly, represents, warrants and agrees with respect to offers and sales outside the United States that: 
 (i) such Initial
Purchaser understands that no action has been or will be taken in any jurisdiction by the Company that would permit a public offering of Securities, or possession or distribution of the Preliminary Memorandum, the Disclosure Package, the Final
Memorandum or any other offering or publicity material relating to the Securities, in any country or jurisdiction where action for that purpose is required; 
 (ii) such Initial Purchaser will comply with all applicable laws and regulations in each jurisdiction in which it acquires, offers, sells or delivers Securities or has in its possession or distributes the Preliminary
Memorandum, the Disclosure Package, the Final Memorandum or any such other material, in all cases at its own expense; 
 (iii) the
Securities have not been registered under the Securities Act and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except in accordance with Rule 144A or Regulation S under the Securities Act;

 (iv) such Initial Purchaser has offered the Securities and will offer and sell the Securities (A) as part of their distribution at
any time and (B) otherwise until 40 days after the later of the commencement of the offering and the Closing Date, only in accordance with Rule 903 of Regulation S or as otherwise permitted in Section 7(a); accordingly, neither such
Initial Purchaser, its Affiliates nor any persons acting on its or their behalf have engaged or will engage in any directed selling efforts (within the meaning of Regulation S) with respect to the Securities, and any such Initial Purchaser, its
Affiliates and any such persons have complied with and will comply with the offering restrictions requirement of Regulation S; 
 (v) such
Initial Purchaser, in relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a 

  

 13 

 
“Member State”), has represented and agreed that with effect from and including the date on which the Prospectus Directive is implemented in
that Member State it has not made and will not make an offer of Securities to the public in that Member State, except that it may, which effect from and including such date, make an offer of Securities to the public in that Member State: 

(A) at any time to legal entities which are authorized or regulated to operate in the financial markets or, if not so authorized or
regulated, whose corporate purpose is solely to invest in securities; 
 (B) at any time to any legal entity which has two or
more of (1) an average of at least 250 employees during the last financial year; (2) a total balance sheet of more than €43,000,000 and (3) an annual net turnover of more than €50,000,000, as shown in its last annual or
consolidated accounts; or 
 (C) at any time in any other circumstances which do not require the publication by the Company of
a prospectus pursuant to Article 3 of the Prospectus Directive. 
 For purposes of the above, the expression an “offer of Securities to the public”
in relation to any Securities in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the Securities to be offered so as to enable an investor to decide to purchase or
subscribe to the Securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State and the expression Prospectus Directive means Directive 2003/71/EC and includes any relevant
implementing measure in that Member State; 
 (vi) such Initial Purchaser has represented and agreed that it has only communicated or caused
to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000) in connection with the issue
or sale of the Securities in circumstances in which Section 21(1) of such Act does not apply to the Company and it has complied and will comply with all applicable provisions of such Act with respect to anything done by it in relation to any
Securities in, from or otherwise involving the United Kingdom; 
 (vii) such Initial Purchaser understands that the Securities have not been
and will not be registered under the Securities and Exchange Law of Japan, and represents that it has not offered or sold, and agrees not to offer or sell, directly or indirectly, any Securities in Japan or for the account of any resident thereof
except pursuant to any exemption from the registration requirements of the Securities and Exchange Law of Japan and otherwise in compliance with applicable provisions of Japanese law; and 
 (viii) such Initial Purchaser agrees that, at or prior to confirmation of sales of the Securities, it will have sent to each distributor, dealer or
person receiving a selling concession, fee or other remuneration that purchases Securities from it during the restricted period a confirmation or notice to substantially the following effect: 
  

 14 

 “The Securities convered hereby have not been registered under the U.S. Securities
Act of 1933 (the “Securities Act”) and may not be offered and sold within the United States or to, or for the account or benefit of, U.S. persons (i) as a part of their distribution at any time or (ii) otherwise until 40 days
after the later of the commencement of the offering and the closing date, except in either case in accordance with Regulation S (or Rule 144A if available) under the Securities Act. Terms used above have the meaning given to them by Regulation
S.” 
 Terms used in this Section 7(b) have the meanings given to them by Regulation S. 
 8. Indemnity and Contribution. (a) The Company will indemnify and hold harmless each Initial Purchaser against any losses, claims, damages or
liabilities, joint or several, to which such Initial Purchaser may become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue
statement or alleged untrue statement of a material fact contained in the Disclosure Package, the Final Memorandum and any Supplemental Offering Materials relating to the Securities, or any amendment or supplement thereto, or arise out of or are
based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse such Initial Purchaser for any legal or other expenses
reasonably incurred by it in connection with investigating or defending any such action or claim as such expenses are incurred; provided, however, that the Company shall not be liable in any such case to the extent that any such loss, claim,
damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Disclosure Package, the Final Memorandum and any Supplemental Offering Materials relating to the
Securities, or in any such amendment or supplement thereto, in reliance upon and in conformity with written information furnished to the Company by such Initial Purchaser expressly for use therein. 
 (b) Each Initial Purchaser will indemnify and hold harmless the Company against any losses, claims, damages or liabilities to which the Company may
become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained
in the Disclosure Package, the Final Memorandum and any Supplemental Offering Materials relating to the Securities, or any amendment or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was
made in the Disclosure Package, the Final Memorandum and any Supplemental Offering Materials relating to the Securities, or any such amendment or supplement thereto, in reliance upon and in conformity with written information furnished to the
Company by such Initial Purchaser expressly for use therein; and will reimburse the Company for any legal or other expenses reasonably incurred by the Company in connection with investigating or defending any such action or claim as such expenses
are incurred. 
  

 15 

 (c) As promptly as reasonably practical after receipt by an indemnified party under paragraph (a) or
(b) above of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement
thereof; but the omission so to notify the indemnifying party shall not relieve it of its obligations (i) under paragraph (a) or (b), as applicable, of this Section 8 unless and only to the extent that the indemnifying party is
materially prejudiced by the failure to notify, or (ii) from any liability which it may have to any indemnified party otherwise than under such applicable subsection. In case any such action shall be brought against any indemnified party and it
shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the
defense thereof, and retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel
related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless (1) the indemnifying
party and the indemnified party shall have mutually agreed to the retention of such counsel or (2) the named parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and
representation of both parties by the same counsel would, in the written opinion of legal counsel to the indemnified party, be inappropriate due to actual or potential differing interests between them. 
 It is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or
related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all such indemnified parties and that all such fees and expenses shall be reimbursed as they are
incurred. Such firm shall be designated in writing by Morgan Stanley or, if Morgan Stanley is not an indemnified party and is not reasonably likely to become an indemnified party, by the Initial Purchasers that are indemnified parties, in the case
of parties indemnified pursuant to paragraph (a) above, and by the Company, in the case of parties indemnified pursuant to paragraph (b) above. No indemnifying party shall, without the written consent of the indemnified party, effect the
settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified party is an
actual or potential party to such action or claim) unless such settlement, compromise or judgment (i) includes an unconditional release of the indemnified party from all liability arising out of such action or claim and (ii) does not
include a statement as to, or an admission of, fault, culpability or a failure to act, by or on behalf of any indemnified party. 
 (d) If
the indemnification provided for in this Section 8 is unavailable or insufficient to hold harmless an indemnified party under subsection (a) or (b) above in respect of any losses, claims, damages or liabilities (or actions in respect
thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is
appropriate to reflect the relative benefits received by the Company on the one hand and each Initial Purchaser on the other from the offering of the Securities to which such 

  

 16 

 
loss, claim, damage or liability (or action in respect thereof) relates. If, however, the allocation provided by the immediately preceding sentence is not
permitted by applicable law, then each indemnifying party shall contribute to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the
Company on the one hand and each Initial Purchaser on the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable
considerations. The relative benefits received by the Company on the one hand and each Initial Purchaser on the other shall be deemed to be in the same proportion as the total net proceeds from the sale of Securities (before deducting expenses)
received by the Company bear to the total commissions and discounts received by such Initial Purchaser in respect thereof. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of
a material fact or the omission or alleged omission to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading relates to information supplied by the Company on the one hand or by any
Initial Purchaser on the other and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and each Initial Purchaser agree that it would not be just and
equitable if contribution pursuant to this subsection (d) were determined by pro rata allocation (even if all Initial Purchasers were treated as one entity for such purpose) or by any other method of allocation which does not take account of
the equitable considerations referred to above in this subsection (d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this subsection
(d) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this subsection (d), an Initial
Purchaser shall not be required to contribute any amount in excess of the amount by which the total price at which the Securities that were offered and sold to the public through such Initial Purchaser exceeds the amount of any damages which such
Initial Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The obligations of each of the Initial Purchasers under this subsection (d) to contribute are several in proportion to the
respective purchases made by or through each such Initial Purchaser to which such loss, claim, damage or liability (or action in respect thereof) relates and are not joint. 
 (e) The obligations of the Company under this Section 8 shall be in addition to any liability which the Company may otherwise have and shall extend,
upon the same terms and conditions, to each person, if any, who controls any Initial Purchaser within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act; and the obligations of each Initial Purchaser under
this Section 8 shall be in addition to any liability which such Initial Purchaser may otherwise have and shall extend, upon the same terms and conditions, to each officer and director of the Company and to each person, if any, who controls the
Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act. 
  

 17 

 9. Termination. This Agreement shall be subject to termination in the Initial Purchasers’
absolute discretion, by written notice to the Company, if (a) after the execution and delivery of this Agreement and prior to the Closing Date (i) trading generally shall have been suspended or materially limited on or by, as the case may
be, any of the New York Stock Exchange, the American Stock Exchange or the Nasdaq National Market, (ii) trading of any securities of the Company shall have been suspended on any exchange or in any over-the-counter market, (iii) a general
moratorium on commercial banking activities in New York shall have been declared by either Federal or New York State authorities, or (iv) there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or
any calamity or crisis that, in the judgment of the Initial Purchasers, is material and adverse and (b) in the case of any of the events specified in clauses (a)(i) through (iv), such event, singly or together with any other such event, makes
it, in the judgment of the Initial Purchasers, impracticable to market the Securities on the terms and in the manner contemplated in the Disclosure Package and the Final Memorandum. 
 10. Effectiveness; Defaulting Initial Purchasers. This Agreement shall become effective upon the execution and delivery hereof by the parties
hereto. 
 If, on the Closing Date, any one or more of the Initial Purchasers shall fail or refuse to purchase Securities that it or they
have agreed to purchase hereunder on such date, and the aggregate principal amount of Securities which such defaulting Initial Purchaser or Initial Purchasers agreed but failed or refused to purchase is not more than one-tenth of the aggregate
principal amount of Securities to be purchased on such date, the other Initial Purchasers shall be obligated severally in the proportions that the principal amount of Securities set forth opposite their respective names in Schedule I bears to the
aggregate principal amount of Securities set forth opposite the names of all such non-defaulting Initial Purchasers, or in such other proportions as you may specify, to purchase the Securities which such defaulting Initial Purchaser or Initial
Purchasers agreed but failed or refused to purchase on such date; provided that in no event shall the principal amount of Securities that any Initial Purchaser has agreed to purchase pursuant to this Agreement be increased pursuant to this
Section 10 by an amount in excess of one-ninth of such principal amount of Securities without the written consent of such Initial Purchaser. If, on the Closing Date any Initial Purchaser or Initial Purchasers shall fail or refuse to purchase
Securities which it or they have agreed to purchase hereunder on such date and the aggregate principal amount of Securities with respect to which such default occurs is more than one-tenth of the aggregate principal amount of Securities to be
purchased on such date, and arrangements satisfactory to you and the Company for the purchase of such Securities are not made within 36 hours after such default, this Agreement shall terminate without liability on the part of any non-defaulting
Initial Purchaser or of the Company. In any such case either you or the Company shall have the right to postpone the Closing Date, but in no event for longer than seven days, in order that the required changes, if any, in the Final Memorandum or in
any other documents or arrangements may be effected. Any action taken under this paragraph shall not relieve any defaulting Initial Purchaser from liability in respect of any default of such Initial Purchaser under this Agreement. 
 If this Agreement shall be terminated by the Initial Purchasers, or any of them, because of any failure or refusal on the part of the Company to comply
with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to 

  

 18 

 
perform its obligations under this Agreement (except if the Company shall be unable to so perform as a result of any default by any Initial Purchaser as
contemplated above), the Company will reimburse the Initial Purchasers or such Initial Purchasers as have so terminated this Agreement with respect to themselves, severally, for all out-of-pocket expenses (including the fees and disbursements of
their counsel) reasonably incurred by such Initial Purchasers in connection with this Agreement or the offering contemplated hereunder. 
 11. Counterparts. This Agreement may be executed in any number of counterparts and by the parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall
constitute one and the same agreement. 
 12. Applicable Law. This Agreement shall be governed by the laws of the State of New York,
including, without limitation, Section 5-1401 of the New York General Obligations Law. 
 13. Severability. In the event that any
one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable, the validity, legality and enforceability of any such provision in every other respect and of the remaining
provisions contained herein shall not be affected or impaired thereby. 
 14. Section References. Unless otherwise indicated,
references in this Agreement to sections are to the sections of this Agreement. 
 15. Headings. The headings in this Agreement are
for convenience of reference only and shall not limit or otherwise affect the construction hereof. 
 16. Notice. All notices and
other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted by any standard form of telecommunication. Notices to the Initial Purchasers shall be directed to Morgan Stanley & Co.
Incorporated at 1585 Broadway, New York, NY 10036 (facsimile no. 212-761-0538), Attention: Global Capital Markets Syndicate Desk, and Merrill Lynch, Pierce, Fenner & Smith Incorporated at 4 World Financial Center, New York, NY 10080
(facsimile no. 212-449-3207), Attention: Global Origination Counsel, with a copy to Shearman & Sterling LLP at 525 Market Street, San Francisco, California 94105 (facsimile no. 415-616-1199), Attention: John D. Wilson; notices to the
Company shall be directed to it at One Amgen Center Drive, Thousand Oaks, California 91320-1799 (facsimile no. 805-499-8011), Attention: Corporate Secretary, with a copy to Latham & Watkins LLP, 633 West Fifth Street, Suite 4000, Los
Angeles, California 90071 (facsimile no. 213-891-8763), Attention: Scott Hodgkins and Latham & Watkins LLP, 885 Third Avenue, New York, New York 10022 (facsimile no. 212-751-4864), Attention: Greg Rodgers. 
 17. No Advisory or Fiduciary Relationship. The Company acknowledges and agrees that (a) the purchase and sale of the Securities pursuant to
this Agreement, including the determination of the offering price of the Securities and any related discounts and commissions, is an arm’s-length commercial transaction between the Company, on the one hand, and the several Initial Purchasers,
on the other hand, (b) in connection with the offering contemplated 
  

 19 

 
hereby and the process leading to such transaction each Initial Purchaser is and has been acting solely as a principal and is not the agent or fiduciary of
the Company, or its stockholders, creditors, employees or any other party, (c) no Initial Purchaser has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or
the process leading thereto (irrespective of whether such Initial Purchaser has advised or is currently advising the Company on other matters) and no Initial Purchaser has any obligation to the Company with respect to the offering contemplated
hereby except the obligations expressly set forth in this Agreement, (d) the Initial Purchasers and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of each of the
Company, and (e) the Initial Purchasers have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to
the extent it deemed appropriate. 
 18. Integration. This Agreement supersedes all prior agreements and understandings (whether
written or oral) between the Company and the Initial Purchasers, or any of them, with respect to the subject matter hereof. 
 [Remainder of
page intentionally left blank] 
  

 20 

			
	 Very truly yours,

	
	 AMGEN INC.

		
	 By:
	 	 /s/ Robert A. Bradway

	 Name:
	 	Robert A. Bradway
	 Title:
	 	Executive Vice President and Chief Financial Officer

 Accepted as of the date hereof 
  

			
	 MORGAN STANLEY & CO. INCORPORATED

	MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED
	
	Acting severally on behalf of themselves and the several Initial Purchasers named in Schedule A hereto.
		
	 By:
	 	Morgan Stanley & Co. Incorporated
		
	 By:
	 	 /s/ Yurij Slyt

	 Name:
	 	Yurij Slyt
	 Title:
	 	Vice President
		
	 By:
	 	 Merrill Lynch, Pierce, Fenner & Smith
 Incorporated

		
	 By:
	 	 /s/ John Kaplan

	 Name:
	 	John Kaplan
	 Title:
	 	Managing Director

 SCHEDULE A 
  

				
	 INITIAL PURCHASERS
	  	 PRINCIPAL AMOUNT OF
 SECURITIES TO BE
 PURCHASED

	 SENIOR FLOATING RATE NOTES DUE 2008
	  		
		
	 Morgan Stanley & Co. Incorporated
	  	$	850,040,000
	 Merrill Lynch, Pierce, Fenner & Smith Incorporated
	  	$	660,000,000
	 Barclays Capital Inc.
	  	$	124,000,000
	 Credit Suisse Securities (USA) LLC
	  	$	124,000,000
	 Goldman, Sachs & Co.
	  	$	124,000,000
	 Citigroup Global Markets Inc.
	  	$	39,320,000
	 J.P. Morgan Securities Inc.
	  	$	39,320,000
	 Lehman Brothers Inc.
	  	$	39,320,000
		  	 	 
	 Total:
	  	$	2,000,000,000
		
	 5.85 % SENIOR NOTES DUE 2017
	  		
		
	 Morgan Stanley & Co. Incorporated
	  	$	467,522,000
	 Merrill Lynch, Pierce, Fenner & Smith Incorporated
	  	$	363,000,000
	 Barclays Capital Inc.
	  	$	68,200,000
	 Credit Suisse Securities (USA) LLC
	  	$	68,200,000
	 Goldman, Sachs & Co.
	  	$	68,200,000
	 Citigroup Global Markets Inc.
	  	$	21,626,000
	 J.P. Morgan Securities Inc.
	  	$	21,626,000
	 Lehman Brothers Inc.
	  	$	21,626,000
		  	 	 
	 Total:
	  	$	1,100,000,000
		
	 6.375% SENIOR NOTES DUE 2037
	  		
		
	 Morgan Stanley & Co. Incorporated
	  	$	382,518,000
	 Merrill Lynch, Pierce, Fenner & Smith Incorporated
	  	$	297,000,000
	 Barclays Capital Inc.
	  	$	55,800,000
	 Credit Suisse Securities (USA) LLC
	  	$	55,800,000
	 Goldman, Sachs & Co.
	  	$	55,800,000
	 Citigroup Global Markets Inc.
	  	$	17,694,000
	 J.P. Morgan Securities Inc.
	  	$	17,694,000
	 Lehman Brothers Inc.
	  	$	17,694,000
		  	 	 
	 Total:
	  	$	900,000,000

 SCHEDULE B 
 PRICING SUPPLEMENT 
 $2,000,000,000 Floating Rate Senior Notes due 2008 
  

			
	Issuer:	 	Amgen Inc.
	Offering Format:	 	144A/ Reg. S with Registration Rights
	Ranking:	 	Senior Unsecured
	Size:	 	$2,000,000,000
	Net Proceeds to Issuer (before expenses):	 	$1,997,000,000
	First Redemption Date:	 	November 28, 2007
	Maturity Date:	 	November 28, 2008
	Price to Public:	 	100%
	Reference Rate:	 	Three-month LIBOR
	Spread to Reference Rate:	 	.08%
	Coupon:	 	Three-month LIBOR + .08%
	Interest Payment Dates:	 	August 28, 2007, November 28, 2007, February 28, 2008, May 28, 2008, August 28, 2008 and November 28, 2008
	Redemption Provisions:	 	
	 Optional Redemption:
	 	The floating rate notes may be redeemed at any time on or after November 28, 2007, in whole or from time to time in part, at a price equal to 100% of their principal amount plus accrued and
unpaid interest to the redemption date.
	Change of Control Repurchase:	 	Upon the occurrence of a change of control triggering event (which requires the occurrence of both a change of control and a below investment grade rating of the notes by Moody’s and
S&P), the issuer will be required to make an offer to purchase the notes at a price equal to 101% of the principal amount plus accrued and unpaid interest, if any, to the date of repurchase.
	Trade Date:	 	May 24, 2007
	Settlement Date:	 	May 30, 2007 (T+3)
	CUSIP:	 	031162 AR1 (144A)/ U03160 AF2 (Reg. S)
	ISIN:	 	US031162AR16 (144A)/ USU03160AF22 (Reg. S)
	Denominations:	 	$2,000 x $1,000
	Ratings:	 	A+ (Negative Watch) / A2 (Negative Outlook)
	Initial Purchasers:	 	Joint Book-Running Managers:
		 	Morgan Stanley & Co. Incorporated
		 	Merrill Lynch, Pierce, Fenner & Smith Incorporated
		 	Barclays Capital Inc.
		 	Credit Suisse Securities (USA) LLC
		 	Goldman, Sachs & Co.
		 	Co-Managers:
		 	Citigroup Global Markets Inc.
		 	J.P. Morgan Securities Inc.
		 	Lehman Brothers Inc.

 The Notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the
“Securities Act”). The Notes may not be offered or sold within the United States or to U.S. persons, except to qualified institutional buyers in reliance on the exemption from registration provided by Rule 144A under the Securities Act
(“Rule 144A”) and to certain persons in transactions outside the United States in reliance on Regulation S under the Securities Act (“Regulation S”). Prospective purchasers are hereby notified that the seller of the Notes may be
relying on the exemption from the provisions of Section 5 of the Securities Act provided by Rule 144A. 

 $1,100,000,000 5.85% Senior Notes due 2017 
  

			
	 Issuer:
	  	Amgen Inc.
	 Offering Format:
	  	144A/ Reg. S with Registration Rights
	 Ranking:
	  	Senior Unsecured
	 Size:
	  	$1,100,000,000
	 Net Proceeds to Issuer (before expenses):
	  	$1,093,323,000
	 Maturity Date:
	  	June 1, 2017
	 Coupon:
	  	5.85%
	 Price to Public:
	  	99.843%
	 Yield to Maturity:
	  	5.871%
	 Interest Payment Dates:
	  	June 1 and December 1, commencing December 1, 2007
	 Redemption Provisions:
	  	
	     Optional Redemption:
	  	 The 2017 notes are redeemable at any time prior to maturity at the
 option of the issuer, in whole or from time to time in part, at a
 redemption price equal to the sum of (1) 100% of the
principal
 amount of notes being redeemed plus accrued and unpaid interest
 to, but not including, the redemption date, and (2) the make-whole
 amount, if any.

	     Make-Whole Amount:
	  	 The excess of (1) the net present value of the principal being
 redeemed or paid and the amount of interest that would have been
 payable if such redemption had not been made, over (2) the
 aggregate principal amount of the 2017 notes being redeemed or
 paid. Net
present value shall be determined by discounting, on a
 semi-annual basis, such principal and interest at the Reinvestment
 Rate from the respective dates on which such principal and interest
 would
have been payable if such redemption had not been made.

	     Reinvestment Rate:
	  	 .15% plus the arithmetic mean of the yields under the respective
 heading “Week Ending” published in the most recent Statistical
 Release under the caption “Treasury Constant
Maturities” for the
 maturity corresponding to the remaining life to maturity, as of the
 payment date of the principal being redeemed or paid.

	 Change of Control Repurchase:
	  	 Upon the occurrence of a change of control triggering event (which
 requires the occurrence of both a change of control and a below
 investment grade rating of the notes by Moody’s and
S&P), the
 issuer will be required to make an offer to purchase the notes at a
 price equal to 101% of the principal amount plus accrued and
 unpaid interest, if any, to the date of
repurchase.

	 Trade Date:
	  	May 24, 2007
	 Settlement Date:
	  	May 30, 2007 (T+3)
	 CUSIP:
	  	031162 AS9 (144A)/ U03160 AG0 (Reg. S)
	 ISIN:
	  	US031162AS98 (144A)/ USU03160AG05 (Reg. S)
	 Denominations:
	  	$2,000 x $1,000
	 Ratings:
	  	A+ (Negative Watch) / A2 (Negative Outlook)
	 Initial Purchasers:
	  	Joint Book-Running Managers:
		  	Morgan Stanley & Co. Incorporated
		  	Merrill Lynch, Pierce, Fenner & Smith Incorporated
		  	Barclays Capital Inc.

			
		  	Credit Suisse Securities (USA) LLC
		  	 Goldman, Sachs & Co.

		  	 Co-Managers:

		  	 Citigroup Global Markets Inc.

		  	 J.P. Morgan Securities Inc.

		  	 Lehman Brothers Inc.

 The Notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the
“Securities Act”). The Notes may not be offered or sold within the United States or to U.S. persons, except to qualified institutional buyers in reliance on the exemption from registration provided by Rule 144A under the Securities Act
(“Rule 144A”) and to certain persons in transactions outside the United States in reliance on Regulation S under the Securities Act (“Regulation S”). Prospective purchasers are hereby notified that the seller of the Notes may be
relying on the exemption from the provisions of Section 5 of the Securities Act provided by Rule 144A. 

 $900,000,000 6.375% Senior Notes due 2037 
  

			
	Issuer:	 	Amgen Inc.
	Offering Format:	 	144A/ Reg. S with Registration Rights
	Ranking:	 	Senior Unsecured
	Size:	 	$900,000,000
	Net Proceeds to Issuer (before expenses):	 	$891,162,000
	Maturity Date:	 	June 1, 2037
	Coupon:	 	6.375%
	Price to Public:	 	99.893%
	Yield to Maturity:	 	6.383%
	Interest Payment Dates:	 	June 1 and December 1, commencing December 1, 2007
	Redemption Provisions:	 	
	 Optional Redemption:
	 	The 2037 notes are redeemable at any time prior to maturity at the option of the issuer, in whole or from time to time in part, at a redemption price equal to the sum of (1) 100% of the
principal amount of notes being redeemed plus accrued and unpaid interest to, but not including, the redemption date, and (2) the make-whole amount, if any.
	 Make-Whole Amount:
	 	The excess of (1) the net present value of the principal being redeemed or paid and the amount of interest that would have been payable if such redemption had not been made, over (2) the
aggregate principal amount of the 2037 notes being redeemed or paid. Net present value shall be determined by discounting, on a semi-annual basis, such principal and interest at the Reinvestment Rate from the respective dates on which such principal
and interest would have been payable if such redemption had not been made.
	 Reinvestment Rate:
	 	.20% plus the arithmetic mean of the yields under the respective heading “Week Ending” published in the most recent Statistical Release under the caption “Treasury Constant
Maturities” for the maturity corresponding to the remaining life to maturity, as of the payment date of the principal being redeemed or paid.
	Change of Control Repurchase:	 	Upon the occurrence of a change of control triggering event (which requires the occurrence of both a change of control and a below investment grade rating of the notes by Moody’s and
S&P), the issuer will be required to make an offer to purchase the notes at a price equal to 101% of the principal amount plus accrued and unpaid interest, if any, to the date of repurchase.
	Trade Date:	 	May 24, 2007
	Settlement Date:	 	May 30, 2007 (T+3)
	CUSIP:	 	031162 AT7 (144A)/ U03160 AH8 (Reg. S)
	ISIN:	 	US031162AT71 (144A)/ USU03160AH87 (Reg. S)
	Denominations:	 	$2,000 x $1,000
	Ratings:	 	A+ (Negative Watch) / A2 (Negative Outlook)
	Initial Purchasers:	 	Joint Book-Running Managers:
		 	Morgan Stanley & Co. Incorporated
		 	Merrill Lynch, Pierce, Fenner & Smith Incorporated
		 	Barclays Capital Inc.

			
		 	Credit Suisse Securities (USA) LLC
		 	Goldman, Sachs & Co.
		 	Co-Managers:
		 	Citigroup Global Markets Inc.
		 	J.P. Morgan Securities Inc.
		 	Lehman Brothers Inc.

 The Notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the
“Securities Act”). The Notes may not be offered or sold within the United States or to U.S. persons, except to qualified institutional buyers in reliance on the exemption from registration provided by Rule 144A under the Securities Act
(“Rule 144A”) and to certain persons in transactions outside the United States in reliance on Regulation S under the Securities Act (“Regulation S”). Prospective purchasers are hereby notified that the seller of the Notes may be
relying on the exemption from the provisions of Section 5 of the Securities Act provided by Rule 144A.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]